Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(1-benzhydryltriazol-4-yl)methyl N-cyclohexylcarbamate
73% inhibition at 0.1 mM
(1-benzyltriazol-4-yl)methyl N-cyclohexylcarbamate
-
(1-phenethyltriazol-4-yl)methyl N-cyclohexylcarbamate
-
(1-phenyltriazol-4-yl)methyl N-cyclohexylcarbamate
-
(1H-benzo[d][1,2,3]triazol-1-yl)(4-(3-phenoxybenzyl)-piperazin-1-yl)-methanone
-
(1H-benzo[d][1,2,3]triazol-1-yl)(4-(4-phenoxybenzyl)-piperazin-1-yl)-methanone hydrochloride
-
(1H-imidazol-1-yl)(4-(3-phenoxybenzyl)piperazin-1-yl)methanone
-
(1H-imidazol-1-yl)(4-(4-phenoxy-benzyl)-piperazin-1-yl)-methanone hydrochloride
-
(3-phenylphenyl)methyl N-cyclohexylcarbamate
65% inhibition at 0.1 mM
(3H-[1,2,3]triazol[4,5-b]pyridin-3-yl)(4-(3-phenoxybenzyl)-piperazin-1-yl)-methanone
-
(3R,4R)-4-acetoxy-3-((10R)-(t-butyldimethylsilyloxy)-ethyl)-azetidin-2-one
-
(4-(bis(benzo[d][1,3]dioxol-5-yl)(hydroxy)methyl)-piperidin-1-yl)(1H-1,2,4-triazol-1-yl)methanone
-
(4-benzhydrylpiperazin-1-yl)(4-phenyl-1H-imidazol-1-yl)methanone
62% activity remaining at 0.01 mM
(4-phenylpiperazin-1-yl)(1H-1,2,4-triazol-1-yl)methanone
-
(benzyl-1,2,4-triazol-3-yl)methyl N-cyclohexylcarbamate
-
(S)-(4-oxo-1-pent-4-enoylazetidin-2-yl)methyl 2-(biphenyl-4-yl)acetate
-
(S)-(4-oxo-1-pent-4-enoylazetidin-2-yl)methyl 3-(1H-indol-3-yl)propanoate
-
(S)-(4-oxo-1-pent-4-enoylazetidin-2-yl)methyl biphenyl-4-carboxylate
-
(S)-(4-oxo-1-pent-4-enoylazetidin-2-yl)methyl-4-phenylbutanoate
-
1,1,1,3,3,3-hexafluoropropan-2-yl 4-(3-phenoxybenzyl)piperazine-1-carboxylate
-
1-(1-phenyl-1,2,4-triazol-3-yl)methyl N-cyclohexylcarbamate
70% inhibition at 0.1 mM
1-[(3S)-1-[4-(1-benzofuran-2-yl)pyrimidin-2-yl]piperidin-3-yl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one
the compound belongs to the ketobenzimidazoles, though containing a carbonyl moiety, that do not covalently modify Ser241. These inhibitors achieve potent inhibition of FAAH activity primarily from shape complementarity to the active site and through numerous hydrophobic interactions exhibiting excellent selectivity and good pharmacokinetic properties, nonmechanism-based inhibition
1-[(3S)-2-oxo-1-(pent-4-enoyl)azetidin-3-yl]ethyl (benzyloxy)acetate
-
1-[(3S)-2-oxo-1-(pent-4-enoyl)azetidin-3-yl]ethyl 3-(1H-indol-3-yl)propanoate
-
1-[(3S)-2-oxo-1-(pent-4-enoyl)azetidin-3-yl]ethyl 4-(pyridin-2-yl)butanoate
-
1-[(3S)-2-oxo-1-(pent-4-enoyl)azetidin-3-yl]ethyl 4-(pyridin-4-yl)butanoate
-
1-[(3S)-2-oxo-1-(pent-4-enoyl)azetidin-3-yl]ethyl biphenyl-4-carboxylate
-
1-[(3S)-2-oxo-1-(pent-4-enoyl)azetidin-3-yl]ethyl biphenyl-4-ylacetate
-
1-[4-[bis(1,3-benzodioxol-5-yl)(hydroxy)methyl]piperidin-1-yl]-3,3,3-trifluoro-2-(trifluoromethyl)propan-1-one
-
1H-benzotriazol-1-yl[4-(diphenylmethyl)piperazin-1-yl]methanone
-
2,2,2-trichloroethyl 4-(bis(benzo[d][1,3]dioxol-5-yl)(hydroxy)methyl)piperidine-1-carboxylate
-
2-(1-benzyltriazol-4-yl)ethyl N-cyclohexylcarbamate
-
2-(1-phenyltriazol-4-yl)ethyl N-cyclohexylcarbamate
-
2-(methylamino)-2-oxoethyl [2-[1-(6-methylpyridin-2-yl)piperidin-4-yl]ethyl]carbamate
-
2H-benzotriazol-2-yl(4-phenylpiperazin-1-yl)methanone
-
2H-benzotriazol-2-yl[4-(diphenylmethyl)piperazin-1-yl]methanone
-
3'-carbamoylbiphenyl-3-yl cyclohexylcarbamate
3'-carbamoylbiphenyl-3-yl undec-10-yn-1-ylcarbamate
-
3-pyridyl 4-(phenylcarbamoyl)piperidine-1-carboxylate
i.e. ASP8477
4-(3-phenoxybenzyl)-N-(4-methoxyphenyl)piperazine-1-carboxamide
-
4-(3-phenoxybenzyl)-N-(4-nitrophenyl)piperazine-1-carboxamide
-
4-(3-phenoxybenzyl)-N-phenylpiperazine-1-carboxamide
-
4-(3-phenyl-1,2,4-thiadiazol-5-yl)-N-(pyridazin-3-yl)piperazine-1-carboxamide
-
4-(benzyloxy)phenyl butylcarbamate
-
4-benzhydryl-N-(4-(trifluoromethyl)phenyl)piperazine-1-carboxamide
86% activity remaining at 0.01 mM
4-benzhydryl-N-(4-butylphenyl)piperazine-1-carboxamide
84% activity remaining at 0.01 mM
4-benzhydryl-N-(4-methoxyphenyl)piperazine-1-carboxamide
89% activity remaining at 0.01 mM
4-benzhydryl-N-(4-nitrophenyl)piperazine-1-carboxamide
84% activity remaining at 0.01 mM
4-benzhydryl-N-(pyridin-2-yl)piperazine-1-carboxamide
87% activity remaining at 0.01 mM
4-benzhydryl-N-(pyridin-3-yl)piperazine-1-carboxamide
87% activity remaining at 0.01 mM
4-benzhydryl-N-phenylpiperazine-1-carboxamide
88% activity remaining at 0.01 mM
4-nitrophenyl 4-(3-phenoxybenzyl)piperazine-1-carboxylate
-
4-nitrophenyl 4-(diphenylmethyl)piperazine-1-carboxylate
-
4-nitrophenyl 4-[bis(1,3-benzodioxol-5-yl)(hydroxy)methyl]piperidine-1-carboxylate
-
4-nitrophenyl 4-[bis(4-fluorophenyl)methyl]piperazine-1-carboxylate
-
4-nitrophenyl-4-(4-phenoxy-benzyl)-piperazine-1-carboxylate
-
4-nitrophenyl-4-(bis(benzo[d][1,3]dioxol-5-yl)methyl)piperidine-1-carboxylate
-
4-[2-(2,4-difluorophenyl)pyridin-4-yl]-N-(pyridazin-3-yl)piperazine-1-carboxamide
-
4-[2-(2,4-difluorophenyl)pyrimidin-4-yl]-N-(pyridazin-3-yl)piperazine-1-carboxamide
-
4-[3-(4-chlorophenoxy)benzyl]-N-(pyridin-3-yl)piperazine-1-carboxamide
-
4-[4-(2,3-difluorophenyl)pyrimidin-2-yl]-N-(pyridazin-3-yl)piperazine-1-carboxamide
-
4-[4-(2,4-difluorophenyl)-1,3-thiazol-2-yl]-N-(3,4-dimethyl-1,2-oxazol-5-yl)piperazine-1-carboxamide
-
4-[4-(2,4-difluorophenyl)pyridin-2-yl]-N-(pyridazin-3-yl)piperazine-1-carboxamide
-
4-[4-(2,4-difluorophenyl)pyrimidin-2-yl]-N-(pyridazin-3-yl)piperazine-1-carboxamide
-
4-[4-(2,5-difluorophenyl)pyrimidin-2-yl]-N-(pyridazin-3-yl)piperazine-1-carboxamide
-
4-[4-(3,4-difluorophenyl)pyrimidin-2-yl]-N-(pyridazin-3-yl)piperazine-1-carboxamide
analgesic effect of 21d in rat inflammatory pain model, overview
4-[4-(3,5-difluorophenyl)pyrimidin-2-yl]-N-(pyridazin-3-yl)piperazine-1-carboxamide
-
4-[6-(2,4-difluorophenyl)pyridin-2-yl]-N-(pyridazin-3-yl)piperazine-1-carboxamide
-
4-[6-(2,4-difluorophenyl)pyrimidin-4-yl]-N-(pyridazin-3-yl)piperazine-1-carboxamide
-
5-(4-hydroxyphenyl)pentanesulfonyl fluoride
i.e. AM3506, irreversible inhibitor for both the rat and the human enzyme, that covalently modifies the enzyme
6-bromo-N-(2-fluorophenyl)-1'H,4H-spiro[1,3-benzodioxine-2,4'-piperidine]-1'-carboxamide
an irreversible covalent inhibitor, binding structure, overview
6-hydroxybiphenyl-3-yl cyclohexylcarbamate
-
7-phenyl-1-(5-pyridin-2-yl-1,3-oxazol-2-yl)heptan-1-one
-
7-phenyl-1-[5-(pyridin-2-yl)-1,3-oxazol-2-yl]heptan-1-one
benzyl 4-(dibenzo[d][1,3]dioxol-5-yl(hydroxy)methyl)-piperidine-1-carboxylate
-
biphenyl-3-yl cyclohexylcarbamate
-
ethyl 4-(1H-1,2,4-triazol-1-ylcarbonyl)piperazine-1-carboxylate
-
ethyl 4-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-ylcarbonyl)piperazine-1-carboxylate
-
hexadecyl sulfonylfluoride
i.e. AM374, is a potent irreversible in vitro and in vivo inhibitor of fatty acid amide hydrolase
methyl arachidonoyl fluorophosphonate
-
N-(3,4-dimethyl-1,2-oxazol-5-yl)-4-(3-phenyl-1,2,4-thiadiazol-5-yl)piperazine-1-carboxamide
-
N-(pyridazin-3-yl)-4-(3-[[5-(trifluoromethyl)pyridin-2-yl]oxy]benzylidene)piperidine-1-carboxamide
-
N-(pyridin-3-yl)-4-(3-[[5-(trifluoromethyl)pyridin-2-yl]oxy]benzyl)piperidine-1-carboxamide
-
N-phenyl-4-(3-phenyl-1,2,4-thiadiazol-5-yl)piperazine-1-carboxamide
-
N-phenyl-4-(3-phenyl-4,5-dihydro-1,2,4-thiadiazol-5-yl)piperazine-1-carboxamide
-
OL-135
7-phenyl-1-[5-(pyridin-2-yl)-1,3-oxazol-2-yl]heptan-1-one
phenylmethane sulfonyl fluoride
irreversible inhibition
pyridin-3-yl 4-(phenylcarbamoyl)piperidine-1-carboxylate
-
[(2S)-4-oxo-1-(pent-4-enoyl)azetidin-2-yl]methyl (benzyloxy)acetate
-
[(2S)-4-oxo-1-(pent-4-enoyl)azetidin-2-yl]methyl 4-(pyridin-2-yl)butanoate
-
[(2S)-4-oxo-1-(pent-4-enoyl)azetidin-2-yl]methyl 4-(pyridin-4-yl)butanoate
-
[1-(2-naphthylmethyl)triazol-4-yl]methyl N-cyclohexylcarbamate
-
[1-(m-tolylmethyl)triazol-4-yl]methyl N-cyclohexylcarbamate
-
[1-(o-tolylmethyl)triazol-4-yl]methyl N-cyclohexylcarbamate
-
[1-(p-tolylmethyl)triazol-4-yl]methyl N-cyclohexylcarbamate
-
[1-[(2,6-difluorophenyl)methyl]triazol-4-yl]methyl N-cyclohexylcarbamate
-
[1-[(2-chlorophenyl)methyl]triazol-4-yl]methyl N-cyclohexylcarbamate
-
[1-[(2-cyanophenyl)methyl]triazol-4-yl]methyl N-cyclohexylcarbamate
-
[1-[(2-fluoro-3-methoxy-phenyl)methyl]triazol-4-yl]methyl N-cyclohexylcarbamate
-
[1-[(2-fluorophenyl)methyl]triazol-4-yl]methyl N-cyclohexylcarbamate
-
[1-[(2-methoxyphenyl)methyl]triazol-4-yl]methyl N-cyclohexylcarbamate
-
[1-[(2-methoxyphenyl)methyl]triazol-4-yl]methyl N-[[1-[(2-methoxyphenyl)methyl]triazol-4-yl]methyl]carbamate
-
[1-[(2-methoxyphenyl)methyl]triazol-4-yl]methyl N-[[1-[(3-methoxyphenyl)methyl]triazol-4-yl]methyl]carbamate
-
[1-[(2-methoxyphenyl)methyl]triazol-4-yl]methyl N-[[1-[(4-methoxyphenyl)methyl]triazol-4-yl]methyl]carbamate
-
[1-[(3,5-difluorophenyl)methyl]triazol-4-yl]methyl N-cyclohexylcarbamate
-
[1-[(3,5-dimethoxyphenyl)methyl]triazol-4-yl]methyl N-cyclohexylcarbamate
-
[1-[(3-chlorophenyl)methyl]triazol-4-yl]methyl N-cyclohexylcarbamate
-
[1-[(3-cyanophenyl)methyl]triazol-4-yl]methyl N-cyclohexylcarbamate
-
[1-[(3-fluorophenyl)methyl]triazol-4-yl]methyl N-cyclohexylcarbamate
-
[1-[(3-methoxyphenyl)methyl]triazol-4-yl]methyl N-cyclohexylcarbamate
-
[1-[(3-methoxyphenyl)methyl]triazol-4-yl]methyl N-[[1-[(2-methoxyphenyl)methyl]triazol-4-yl]methyl]carbamate
-
[1-[(3-methoxyphenyl)methyl]triazol-4-yl]methyl N-[[1-[(3-methoxyphenyl)methyl]triazol-4-yl]methyl]carbamate
-
[1-[(3-methoxyphenyl)methyl]triazol-4-yl]methyl N-[[1-[(4-methoxyphenyl)methyl]triazol-4-yl]methyl]carbamate
-
[1-[(4-chlorophenyl)methyl]triazol-4-yl]methyl N-cyclohexylcarbamate
-
[1-[(4-cyanophenyl)methyl]triazol-4-yl]methyl N-cyclohexylcarbamate
-
[1-[(4-fluorophenyl)methyl]triazol-4-yl]methyl N-cyclohexylcarbamate
-
[1-[(4-methoxyphenyl)methyl]triazol-4-yl]methyl N-cyclohexylcarbamate
-
[4-(3-phenoxybenzyl)piperazin-1-yl](1H-1,2,4-triazol-1-yl)methanone
-
[4-(diphenylmethyl)piperazin-1-yl](1H-1,2,4-triazol-1-yl)methanone
-
[4-(diphenylmethyl)piperazin-1-yl](1H-imidazol-1-yl)methanone
-
[4-[bis(1,3-benzodioxol-5-yl)methyl]piperidin-1-yl](1H-1,2,4-triazol-1-yl)methanone
-
[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl](1H-1,2,4-triazol-1-yl)methanone
-
(1-benzothiophen-6-ylamino)([(E)-[1-(biphenyl-3-yl)ethylidene]amino]oxy)methanone
-
-
(1-benzylpiperidin-4-yl)[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl]methanone
-
-
(10Z)-1,1,1-trifluorononadec-10-en-2-one
-
-
(10Z)-1-bromononadec-10-en-2-one
-
-
(10Z)-2-oxononadec-10-enamide
-
-
(4-benzylpiperazin-1-yl)[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl]methanone
-
-
(5Z,8Z,11Z,14Z)-1-pyridazin-3-ylicosa-5,8,11,14-tetraen-1-one
-
-
(5Z,8Z,11Z,14Z)-1-[1,3]oxazolo[4,5-b]pyridin-2-ylicosa-5,8,11,14-tetraen-1-one
-
-
(5Z,8Z,11Z,14Z)-1-[1,3]oxazolo[4,5-c]pyridin-2-ylicosa-5,8,11,14-tetraen-1-one
-
-
(5Z,8Z,11Z,14Z)-1-[1,3]oxazolo[5,4-c]pyridin-2-ylicosa-5,8,11,14-tetraen-1-one
-
-
(9E)-1-pyridazin-3-yloctadec-9-en-1-one
-
-
(9E)-1-[1,3]oxazolo[4,5-b]pyridin-2-yloctadec-9-en-1-one
-
-
(9Z)-1-(1,3-benzothiazol-2-yl)octadec-9-en-1-one
-
-
(9Z)-1-(1,3-benzoxazol-2-yl)octadec-9-en-1-one
-
-
(9Z)-1-(1,3-oxazol-2-yl)octadec-9-en-1-one
-
-
(9Z)-1-(1,3-thiazol-2-yl)octadec-9-en-1-one
-
-
(9Z)-1-(1-methyl-1H-benzimidazol-2-yl)octadec-9-en-1-one
-
-
(9Z)-1-(1-methyl-1H-imidazol-2-yl)octadec-9-en-1-one
-
-
(9Z)-1-(1-methyl-1H-tetrazol-5-yl)octadec-9-en-1-one
-
-
(9Z)-1-(1H-benzimidazol-2-yl)octadec-9-en-1-one
-
-
(9Z)-1-(1H-tetrazol-5-yl)octadec-9-en-1-one
-
-
(9Z)-1-(2-methyl-2H-tetrazol-5-yl)octadec-9-en-1-one
-
-
(9Z)-1-(4,5-dihydro-1,3-oxazol-2-yl)octadec-9-en-1-one
-
-
(9Z)-1-(4-methyl-1,3-benzoxazol-2-yl)octadec-9-en-1-one
-
-
(9Z)-1-(5-methyl-1,3-benzoxazol-2-yl)octadec-9-en-1-one
-
-
(9Z)-1-(6-methyl-1,3-benzoxazol-2-yl)octadec-9-en-1-one
-
-
(9Z)-1-(7-methyl-1,3-benzoxazol-2-yl)octadec-9-en-1-one
-
-
(9Z)-1-phenyloctadec-9-en-1-one
-
-
(9Z)-1-pyrazin-2-yloctadec-9-en-1-one
-
-
(9Z)-1-pyridazin-3-yloctadec-9-en-1-one
-
-
(9Z)-1-pyridin-2-yloctadec-9-en-1-one
-
-
(9Z)-1-pyrimidin-2-yloctadec-9-en-1-one
-
-
(9Z)-1-pyrimidin-4-yloctadec-9-en-1-one
-
-
(9Z)-1-[1,3]oxazolo[4,5-b]pyridin-2-yloctadec-9-en-1-one
-
-
(9Z)-1-[1,3]oxazolo[4,5-c]pyridin-2-yloctadec-9-en-1-one
-
-
(9Z)-1-[1,3]oxazolo[5,4-b]pyridin-2-yloctadec-9-en-1-one
-
-
(9Z)-1-[1,3]oxazolo[5,4-c]pyridin-2-yloctadec-9-en-1-one
-
-
(dodecylamino)[[(E)-[1-[3-(thiophen-2-yl)phenyl]ethylidene]amino]oxy]methanone
-
-
(phenylamino)[[(4-phenylcyclohexylidene)amino]oxy]methanone
-
-
(phenylamino)[[(E)-[1-[3-(thiophen-2-yl)phenyl]ethylidene]amino]oxy]methanone
-
-
(phenylamino)[[(E)-[1-[4-(thiophen-2-yl)phenyl]ethylidene]amino]oxy]methanone
-
-
([(E)-[1-(2,2'-bithiophen-5-yl)ethylidene]amino]oxy)(naphthalen-1-ylamino)methanone
-
-
([(E)-[1-(4-cyclohexylphenyl)ethylidene]amino]oxy)(naphthalen-1-ylamino)methanone
-
-
([(E)-[1-(biphenyl-3-yl)ethylidene]amino]oxy)(diphenylamino)methanone
-
-
([(E)-[1-(biphenyl-3-yl)ethylidene]amino]oxy)(naphthalen-1-ylamino)methanone
-
-
([(E)-[1-(biphenyl-3-yl)ethylidene]amino]oxy)(phenylamino)methanone
-
-
([(E)-[1-(biphenyl-3-yl)ethylidene]amino]oxy)(piperidin-1-yl)methanone
-
-
([(E)-[1-(biphenyl-3-yl)ethylidene]amino]oxy)[(4-fluorophenyl)amino]methanone
-
-
([(E)-[1-(biphenyl-3-yl)ethylidene]amino]oxy)[(4-methoxyphenyl)amino]methanone
-
-
([(E)-[1-(biphenyl-3-yl)ethylidene]amino]oxy)[(5-phenylpentyl)amino]methanone
-
-
([(E)-[1-(biphenyl-4-yl)ethylidene]amino]oxy)(dimethylamino)methanone
-
-
([(E)-[1-(biphenyl-4-yl)ethylidene]amino]oxy)(naphthalen-1-ylamino)methanone
-
-
([(E)-[1-(biphenyl-4-yl)ethylidene]amino]oxy)(phenylamino)methanone
-
-
1,1,1-trifluoro-N-([1-[2-oxo-3-(4-phenoxyphenoxy)propyl]-1H-indazol-5-yl]carbamoyl)methanesulfonamide
-
-
1,2,3,4-tetrahydronaphthalen-1-yl [4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl]carbamate
-
59.6% inhibition at 0.01 mM
1-(1,3-benzoxazol-2-yl)octadecan-1-one
-
-
1-(1H-benzimidazol-1-yl)-3-(4-octylphenoxy)propan-2-one
-
-
1-(1H-benzotriazol-1-yl)-3-(4-octylphenoxy)propan-2-one
-
-
1-(1H-benzotriazol-1-yl)-3-(4-phenoxyphenoxy)propan-2-one
-
-
1-(1H-benzotriazol-1-yl)-3-[(3'-chloro[1,1'-biphenyl]-4-yl)oxy]propan-2-one
-
-
1-(1H-benzotriazol-1-yl)-3-[(3'-fluoro[1,1'-biphenyl]-4-yl)oxy]propan-2-one
-
-
1-(1H-benzotriazol-1-yl)-3-[(4'-chloro[1,1'-biphenyl]-4-yl)oxy]propan-2-one
-
-
1-(1H-benzotriazol-1-yl)-3-[(4'-fluoro[1,1'-biphenyl]-4-yl)oxy]butan-2-one
-
-
1-(1H-benzotriazol-1-yl)-3-[(4'-fluoro[1,1'-biphenyl]-4-yl)oxy]propan-2-one
-
-
1-(1H-benzotriazol-1-yl)-3-[([1,1'-biphenyl]-4-yl)oxy]butan-2-one
-
-
1-(1H-benzotriazol-1-yl)-3-[([1,1'-biphenyl]-4-yl)oxy]pentan-2-one
-
-
1-(1H-benzotriazol-1-yl)-3-[([1,1'-biphenyl]-4-yl)oxy]propan-2-one
-
-
1-(1H-imidazol-1-yl)-3-(4-octylphenoxy)propan-2-one
-
-
1-(1H-imidazo[4,5-b]pyridin-1-yl)-3-(4-octylphenoxy)propan-2-one
-
-
1-(1H-indazol-1-yl)-3-(4-octylphenoxy)propan-2-one
-
-
1-(1H-indazol-1-yl)-3-(4-phenoxyphenoxy)propan-2-one
-
-
1-(3H-imidazo[4,5-b]pyridin-3-yl)-3-(4-octylphenoxy)propan-2-one
-
-
1-(4-octylphenoxy)-3-(1H-1,2,4-triazol-1-yl)propan-2-one
-
-
1-(4-octylphenoxy)-3-(1H-pyrazol-1-yl)propan-2-one
-
-
1-(4-octylphenoxy)-3-(1H-pyrazolo[3,4-b]pyridin-1-yl)propan-2-one
-
-
1-(4-octylphenoxy)-3-(1H-pyrazolo[4,3-b]pyridin-1-yl)propan-2-one
-
-
1-(4-octylphenoxy)-3-(1H-tetrazol-1-yl)propan-2-one
-
-
1-(4-octylphenoxy)-3-(1H-[1,2,3]triazolo[4,5-b]pyridin-1-yl)propan-2-one
-
-
1-(4-octylphenoxy)-3-(2H-1,2,3-triazol-2-yl)propan-2-one
-
-
1-(4-octylphenoxy)-3-(2H-tetrazol-2-yl)propan-2-one
-
-
1-(4-octylphenoxy)-3-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)propan-2-one
-
-
1-(4-phenoxyphenoxy)-3-(2H-tetrazol-2-yl)propan-2-one
-
-
1-(5-nitro-1H-indazol-1-yl)-3-(4-phenoxyphenoxy)propan-2-one
-
-
1-([1,3]oxazolo[4,5-b]pyridin-2-yl)-6-phenylhexan-1-one
-
-
1-benzothiophen-4-yl [4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl]carbamate
-
-
1-pyridazin-3-yloctadecan-1-one
-
-
1-[(3R)-1-[4-(1-benzofuran-2-yl)pyrimidin-2-yl]piperidin-3-yl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one
-
-
1-[([1,1'-biphenyl]-4-yl)oxy]-3-(1H-tetrazol-1-yl)propan-2-one
-
-
1-[([1,1'-biphenyl]-4-yl)oxy]-3-(2H-tetrazol-2-yl)butan-2-one
-
-
1-[([1,1'-biphenyl]-4-yl)oxy]-3-(2H-tetrazol-2-yl)propan-2-one
-
-
1-[1,3]oxazolo[4,5-b]pyridin-2-yl-4-phenylbutan-1-one
-
-
1-[1,3]oxazolo[4,5-b]pyridin-2-yl-5-phenylpentan-1-one
-
-
1-[1,3]oxazolo[4,5-b]pyridin-2-yl-6-phenylhexan-1-one
-
-
1-[1,3]oxazolo[4,5-b]pyridin-2-yl-7-phenylheptan-1-one
-
-
1-[1,3]oxazolo[4,5-b]pyridin-2-yl-8-phenyloctan-1-one
-
-
1-[1,3]oxazolo[4,5-b]pyridin-2-yl-9-phenylnonan-1-one
-
-
1-[1,3]oxazolo[4,5-b]pyridin-2-yldec-9-en-1-one
-
-
1-[1,3]oxazolo[4,5-b]pyridin-2-yldec-9-yn-1-one
-
-
1-[1,3]oxazolo[4,5-b]pyridin-2-yldecan-1-one
-
-
1-[1,3]oxazolo[4,5-b]pyridin-2-yldodecan-1-one
-
-
1-[1,3]oxazolo[4,5-b]pyridin-2-ylethanone
-
-
1-[1,3]oxazolo[4,5-b]pyridin-2-ylheptan-1-one
-
-
1-[1,3]oxazolo[4,5-b]pyridin-2-ylhexadecan-1-one
-
-
1-[1,3]oxazolo[4,5-b]pyridin-2-ylhexan-1-one
-
-
1-[1,3]oxazolo[4,5-b]pyridin-2-yloctadec-9-yn-1-one
-
-
1-[1,3]oxazolo[4,5-b]pyridin-2-yloctadecan-1-one
-
-
1-[1,3]oxazolo[4,5-b]pyridin-2-yloctan-1-one
-
-
1-[1,3]oxazolo[4,5-b]pyridin-2-ylpentan-1-one
-
-
1-[1,3]oxazolo[4,5-b]pyridin-2-yltetradecan-1-one
-
-
1-[2-oxo-3-(4-phenoxyphenoxy)propyl]-1H-indazole-5-carboxylic acid
-
-
1-[3-(4-octylphenoxy)-2-oxopropyl]indole-5-carboxylic acid
-
-
1-[3-[(4'-chlorobiphenyl-4-yl)oxy]-2-oxopropyl]-1H-indole-5-carboxylic acid
-
-
1H-benzimidazol-4-yl [4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl]carbamate
-
-
1H-indol-4-yl [4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl]carbamate
-
-
2,3-dihydro-1,4-benzodioxin-5-yl [4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl]carbamate
-
-
2-(1H-benzotriazol-1-yl)-1-(5-phenoxy-1,3-benzoxazol-2-yl)ethan-1-one
-
-
2-hydroxy-N-[1-[2-oxo-3-(4-phenoxyphenoxy)propyl]-1H-indazol-5-yl]acetamide
-
-
2-methoxy-N-[1-[2-oxo-3-(4-phenoxyphenoxy)propyl]-1H-indazol-5-yl]acetamide
-
-
3'-carbamoyl[1,1'-biphenyl]-3-yl cyclohexylcarbamate
-
-
3'-[(1E)-N-[(phenylcarbamoyl)oxy]ethanimidoyl]biphenyl-3-carboxamide
-
-
3-(1H-benzotriazol-1-yl)-1-[([1,1'-biphenyl]-4-yl)oxy]butan-2-one
-
-
3-pyridyl 4-(phenylcarbamoyl)piperidine-1-carboxylate
i.e. ASP8477
3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]-N,N-diethylazetidine-1-carboxamide
-
-
3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]-N-ethyl-N-(2-hydroxyethyl)azetidine-1-carboxamide
-
-
3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]-N-methyl-N-(2-phenylethyl)azetidine-1-carboxamide
-
-
3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]-N-methyl-N-phenylazetidine-1-carboxamide
-
-
3-[([1,1'-biphenyl]-4-yl)oxy]-1-(1H-tetrazol-1-yl)butan-2-one
-
-
3-[([1,1'-biphenyl]-4-yl)oxy]-1-(2H-tetrazol-2-yl)butan-2-one
-
-
4-(3-phenyl-[1,2,4]thiadiazol-5-yl)piperazine-1-carboxylic acid phenylamide
-
4-carbamoylnaphthalen-1-yl [4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl]carbamate
-
-
4-fluoronaphthalen-1-yl [4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl]carbamate
-
-
4-hydroxynaphthalen-1-yl [4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl]carbamate
-
-
4-methoxynaphthalen-1-yl [4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl]carbamate
-
-
4-[([4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl]carbamoyl)oxy]naphthalene-1-carboxylic acid
-
-
5,6,7,8-tetrahydronaphthalen-1-yl [4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl]carbamate
-
-
7-phenyl-1-[5-(pyridin-2-yl)-1,3-oxazol-2-yl]heptan-1-one
azepan-1-yl[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl]methanone
-
-
azetidin-1-yl[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl]methanone
-
-
ethyl (10Z)-2-oxononadec-10-enoate
-
-
methyl [1-[2-oxo-3-(4-phenoxyphenoxy)propyl]-1H-indazol-5-yl]carbamate
-
-
N,N-dibenzyl-3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidine-1-carboxamide
-
-
N-(phenylcarbamoyl)-3'-[(1E)-N-[(phenylcarbamoyl)oxy]ethanimidoyl]biphenyl-3-carboxamide
-
-
N-([1-[2-oxo-3-(4-phenoxyphenoxy)propyl]-1H-indazol-5-yl]carbamoyl)benzenesulfonamide
-
-
N-([1-[2-oxo-3-(4-phenoxyphenoxy)propyl]-1H-indazol-5-yl]carbamoyl)methanesulfonamide
-
-
N-benzyl-3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]-N-(2-hydroxyethyl)azetidine-1-carboxamide
-
-
N-benzyl-3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]-N-methylazetidine-1-carboxamide
-
-
N-benzyl-3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]-N-[2-(dimethylamino)ethyl]azetidine-1-carboxamide
-
-
N-benzyl-3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidine-1-carboxamide
-
-
N-benzyl-3-[(R)-(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]-N-methylazetidine-1-carboxamide
-
-
N-benzyl-3-[(S)-(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]-N-methylazetidine-1-carboxamide
-
-
N-cyclohexyl-N'-[1-[2-oxo-3-(4-phenoxyphenoxy)propyl]-1H-indazol-5-yl]urea
-
-
N-ethyl-N'-[1-[2-oxo-3-(4-phenoxyphenoxy)propyl]-1H-indazol-5-yl]urea
-
-
N-tert-butyl-3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidine-1-carboxamide
-
-
N-[1-[2-oxo-3-(4-phenoxyphenoxy)propyl]-1H-indazol-5-yl]-N'-phenylurea
-
-
N-[1-[2-oxo-3-(4-phenoxyphenoxy)propyl]-1H-indazol-5-yl]acetamide
-
-
N-[4-(4-methoxy-1,3-benzothiazol-2-yl)phenyl]-1-(thiophen-2-ylsulfonyl)piperidine-4-carboxamide
-
a reversible, albeit slowly dissociating inhibitor of FAAH, reversibly and noncovalently inhibiting, molecular docking and computational modeling of interactions of the benzothiazole analogue 1 with humanized rat FAAH by induced fit docking, overview. Failure to observe the formation of covalent enzyme-inhibitor adduct or putative cleavage product using electrospray mass spectrometric techniques
naphthalen-1-yl (3-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]propyl)carbamate
-
-
naphthalen-1-yl (4-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]butyl)carbamate
-
-
naphthalen-1-yl [3-[4-(2,3-dichlorophenyl)piperazin-1-yl]propyl]carbamate
-
-
naphthalen-1-yl [3-[4-(3-methoxyphenyl)piperazin-1-yl]propyl]carbamate
-
-
naphthalen-1-yl [3-[4-(3-methylphenyl)piperazin-1-yl]propyl]carbamate
-
-
naphthalen-1-yl [4-[4-(3-methoxyphenyl)piperazin-1-yl]butyl]carbamate
-
-
naphthalen-1-yl [4-[4-(3-methylphenyl)piperazin-1-yl]butyl]carbamate
-
-
oleoyl ethylamide
-
FAAH inhibitor
oleoyl oxazolopyridine
-
, i.e. oloxa, a potent noncompetitive inhibitor, almost complete inhibition at 50 nM
palmitoyl ethanolamide
-
a non-CB1 non-CB2 cannabinoid-like compound
phenyl [1-[2-oxo-3-(4-phenoxyphenoxy)propyl]-1H-indazol-5-yl]carbamate
-
-
phenyl [4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl]carbamate
-
-
piperidin-1-yl[[(E)-[1-[3-(thiophen-2-yl)phenyl]ethylidene]amino]oxy]methanone
-
-
pyridin-3-yl 4-(phenylcarbamoyl)piperidine-1-carboxylate
-
VER-156084
-
a tetrasubstituted azetidine urea FAAH inhibitor
[1-(4-phenoxyphenoxy)-3-(2H-tetrazol-2-yl)propan-2-yl]cyanamide
-
-
-
[3-[(2-chlorophenyl)(4-chlorophenyl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
-
-
[3-[(2-chloropyridin-3-yl)(2-methylphenyl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
-
-
[3-[(2-chloropyridin-3-yl)(3,4-dichlorophenyl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
-
-
[3-[(2-chloropyridin-3-yl)(3-methoxyphenyl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
-
-
[3-[(2-chloropyridin-3-yl)(phenyl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
-
-
[3-[(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
-
-
[3-[(3-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
-
-
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](1,3-dihydro-2H-isoindol-2-yl)methanone
-
-
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](2-hydroxypiperidin-1-yl)methanone
-
-
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](2-methylpiperidin-1-yl)methanone
-
-
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](3,4-dihydroisoquinolin-2(1H)-yl)methanone
-
-
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](3-hydroxypiperidin-1-yl)methanone
-
-
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](3-hydroxypyrrolidin-1-yl)methanone
-
-
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](3-methylpiperidin-1-yl)methanone
-
-
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](4,4-difluoropiperidin-1-yl)methanone
-
-
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](4-fluoropiperidin-1-yl)methanone
-
-
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](4-hydroxypiperidin-1-yl)methanone
-
-
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](4-methylpiperazin-1-yl)methanone
-
-
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](4-methylpiperidin-1-yl)methanone
-
-
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](morpholin-4-yl)methanone
-
-
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](pyrrolidin-1-yl)methanone
-
-
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl][4-(hydroxymethyl)piperidin-1-yl]methanone
-
-
[3-[(4-chlorophenyl)(2-methylphenyl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
-
-
[3-[(6-chloropyridin-3-yl)(2-methylphenyl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
-
-
[3-[(S)-(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
-
-
[3-[1,3-benzodioxol-5-yl(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
-
-
[3-[phenyl(pyridin-3-yl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
-
-
[[(E)-[1-[4-(2,5-dimethyl-1H-pyrrol-1-yl)phenyl]ethylidene]amino]oxy](naphthalen-1-ylamino)methanone
-
-
3'-carbamoylbiphenyl-3-yl cyclohexylcarbamate
-
3'-carbamoylbiphenyl-3-yl cyclohexylcarbamate
irreversible inhibitor
3'-carbamoylbiphenyl-3-yl cyclohexylcarbamate
exerts a combination of anxiolytic-like, anti-depressant-like, and analgesic effects, due to its ability to inhibit FAAH activity in the CNS and peripheral tissues. Covalent enzyme binding at Ser241 leading to irreversible inhibition, the attack at the carbonyl group by Ser 241 leads to the formation of carbamoylated, catalytically inactive FAAH and releasing the O-biphenyl moiety as the leaving group
7-phenyl-1-[5-(pyridin-2-yl)-1,3-oxazol-2-yl]heptan-1-one
-
7-phenyl-1-[5-(pyridin-2-yl)-1,3-oxazol-2-yl]heptan-1-one
reversible inhibitor
7-phenyl-1-[5-(pyridin-2-yl)-1,3-oxazol-2-yl]heptan-1-one
-
-
7-phenyl-1-[5-(pyridin-2-yl)-1,3-oxazol-2-yl]heptan-1-one
-
OL-135, an alpha-keto-heterocycle that is a covalent reversible inhibitor of FAAH
URB597
-
-
URB597
-
a carbamate inhibiting FAAH covalently and irreversibly, time-dependent inhibition, overview
additional information
design, synthesis, and biological evaluation of a series of piperazine ureas as fatty acid amide hydrolase inhibitors, overview
-
additional information
O-(triazolyl)methyl carbamates as potent fatty acid amide hydrolase inhibitors, overview
-
additional information
-
O-(triazolyl)methyl carbamates as potent fatty acid amide hydrolase inhibitors, overview
-
additional information
piperazine and piperidine carboxamides and carbamates as enzyme inhibitors, molecular modeling, overview. Diverse leaving groups are tolerated for FAAH inhibitors
-
additional information
sulfonyl fluoride inhibitors of fatty acid amide hydrolase, structure-activity relationship, docking and molecular modeling, overview
-
additional information
-
sulfonyl fluoride inhibitors of fatty acid amide hydrolase, structure-activity relationship, docking and molecular modeling, overview
-
additional information
synthesis of a series of lipophilic ester derivatives of (S)-1-(pent-40-enoyl)-4-(hydroxymethyl)-azetidin-2-one in three steps from (S)-4-(benzyloxycarbonyl)-azetidin-2-one, evaluation as reversible, beta-lactamic inhibitors of endocannabinoid-degrading enzymes, fatty acid amide hydrolase and and monoacylglycerol lipase, docking studies, overview. No inhibition by 1b, 1d, and 1f
-
additional information
-
synthesis of a series of lipophilic ester derivatives of (S)-1-(pent-40-enoyl)-4-(hydroxymethyl)-azetidin-2-one in three steps from (S)-4-(benzyloxycarbonyl)-azetidin-2-one, evaluation as reversible, beta-lactamic inhibitors of endocannabinoid-degrading enzymes, fatty acid amide hydrolase and and monoacylglycerol lipase, docking studies, overview. No inhibition by 1b, 1d, and 1f
-
additional information
-
fatty acid-derived FAAH inhibitors
-
additional information
-
analysis of the enzyme inhibition by quantum mechanics/molecular mechanics (QM/MM) modelling
-
additional information
-
1-(3-biaryloxy-2-oxopropyl)indole-5-carboxylic acids and related compounds can act as dual inhibitors of human cytosolic phospholipase A2alpha, EC 3.1.1.4, and fatty acid amide hydrolase, overview. Substituents at the indole 3- and 5-positions and replacement of the indole scaffold of this compound by other heterocycles strongly influences the inhibitory potency against FAAH
-
additional information
-
a series of oxime carbamates as non-competitive, reversible inhibitors, and show remarkable selectivity for FAAH over the other components of the endocannabinoid system
-
additional information
-
mechanism of inhibition of fatty acid amide hydrolase by sulfonamide-containing benzothiazoles, long residence time derived from increased kinetic barrier and not exclusively from thermodynamic potency, transition-state analogues, overview
-
additional information
-
tetra-substituted azetidine ureas with in vivo activity as fatty acid amide hydrolase inhibitors, overview
-
additional information
-
indazole-5-carboxylic acids with 3-aryloxy-2-oxopropyl residues in position 1 are reported to be potent dual inhibitors of cytosolic phospholipase A2alpha and fatty acid amide hydrolase. The carboxylic acid functionality of the lead compounds is of special importance for a pronounced inhibition of cytosolic phospholipase A2alpha and fatty acid amide hydrolase
-
additional information
-
the replacement of the activated ketone functionality of the fatty acid amide hydrolase inhibitors 1-(1H-benzotriazol-1-yl)-3-(4-phenoxyphenoxy)propan-2-one and 1-(4-phenoxyphenoxy)-3-(2H-tetrazol-2-yl)propan-2-one, by a-ketoheterocycle, cyanamide, and nitrile is not well tolerated. The resulting compounds are only weakly or even not active against the enzyme
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Abortion, Habitual
Nuclear localisation of the endocannabinoid metabolizing enzyme fatty acid amide hydrolase (FAAH) in invasive trophoblasts and an association with recurrent miscarriage.
Abortion, Spontaneous
Characterization of the endocannabinoid system in early human pregnancy.
Abortion, Spontaneous
Nuclear localisation of the endocannabinoid metabolizing enzyme fatty acid amide hydrolase (FAAH) in invasive trophoblasts and an association with recurrent miscarriage.
Abortion, Spontaneous
The endocannabinoid-CB(1) receptor system in pre- and postnatal life.
Adenomatous Polyps
Possible endocannabinoid control of colorectal cancer growth.
Alveolar Bone Loss
PF-3845, a Fatty Acid Amide Hydrolase Inhibitor, Directly Suppresses Osteoclastogenesis through ERK and NF-?B Pathways In Vitro and Alveolar Bone Loss In Vivo.
Alzheimer Disease
Anti-Inflammatory Effects of Fatty Acid Amide Hydrolase Inhibition in Monocytes/Macrophages from Alzheimer's Disease Patients.
Alzheimer Disease
Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains.
Alzheimer Disease
Cannabinoid control of motor function at the basal ganglia.
Alzheimer Disease
Combining fatty acid amide hydrolase (FAAH) inhibition with peroxisome proliferator-activated receptor (PPAR) activation: a new potential multi-target therapeutic strategy for the treatment of Alzheimer's disease.
Alzheimer Disease
Design and synthesis of new carbamates as inhibitors for fatty acid amide hydrolase and cholinesterases: Molecular dynamic, in vitro and in vivo studies.
Alzheimer Disease
Epigenetic regulation of fatty acid amide hydrolase in Alzheimer disease.
Alzheimer Disease
Fatty Acid Amide Hydrolase (FAAH) Inhibition Modulates Amyloid-Beta-Induced Microglia Polarization.
Alzheimer Disease
Glial expression of cannabinoid CB(2) receptors and fatty acid amide hydrolase are beta amyloid-linked events in Down's syndrome.
Alzheimer Disease
Normal aging in rats and pathological aging in human Alzheimer's disease decrease FAAH activity: modulation by cannabinoid agonists.
Alzheimer Disease
Role of interleukin 1-beta in the inflammatory response in a fatty acid amide hydrolase-knockout mouse model of Alzheimer's disease.
amidase deficiency
Fatty acid amide hydrolase deficiency enhances intraplaque neutrophil recruitment in atherosclerotic mice.
amidase deficiency
Fatty acid amide hydrolase deficiency limits early pregnancy events.
Arrhythmias, Cardiac
Endocannabinoids and the heart.
Arthritis, Experimental
Fatty acid amide hydrolase blockade attenuates the development of collagen-induced arthritis and related thermal hyperalgesia in mice.
Atherosclerosis
Endocannabinoids and the heart.
Brain Injuries, Traumatic
Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: A neuroprotective therapeutic modality.
Brain Injuries, Traumatic
Inhibition of fatty acid amide hydrolase by PF-3845 alleviates the nitrergic and proinflammatory response in rat hippocampus following acute stress.
Brain Injuries, Traumatic
The fatty acid amide hydrolase inhibitor PF-3845 promotes neuronal survival, attenuates inflammation and improves functional recovery in mice with traumatic brain injury.
Breast Neoplasms
Biosynthesis and degradation of bioactive fatty acid amides in human breast cancer and rat pheochromocytoma cells--implications for cell proliferation and differentiation.
Breast Neoplasms
Effect on cancer cell proliferation of palmitoylethanolamide, a fatty acid amide interacting with both the cannabinoid and vanilloid signalling systems.
Breast Neoplasms
High levels of ?-glutamyl hydrolase (GGH) are associated with poor prognosis and unfavorable clinical outcomes in invasive breast cancer.
Breast Neoplasms
Inhibition Of Fatty Acid Amide Hydrolase Activates Nrf2 Signaling And Induces Heme Oxygenase 1 Transcription In Breast Cancer Cells.
Breast Neoplasms
Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells.
Carcinoma
Expression and function of fatty acid amide hydrolase in prostate cancer.
Catalepsy
Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase.
Cataract
Exacerbation of Background Nuclear Cataracts in Sprague-Dawley Rats in Embryo-Fetal Development Studies With JNJ-42165279, a Fatty Acid Amide Hydrolase Inhibitor.
Central Nervous System Diseases
Discovery of heterocyclic carbohydrazide derivatives as novel selective fatty acid amide hydrolase inhibitors: design, synthesis and anti-neuroinflammatory evaluation.
Cerebral Cortical Thinning
Brain structural changes in cannabis dependence: association with MAGL.
Cholestasis
Effects of URB597 as an inhibitor of fatty acid amide hydrolase on modulation of nociception in a rat model of cholestasis.
Colitis
Comorbid anxiety-like behavior in a rat model of colitis is mediated by an upregulation of corticolimbic fatty acid amide hydrolase.
Colitis
Elevation of arachidonoylethanolamide levels by activation of the endocannabinoid system protects against colitis and ameliorates remote organ lesions in mice.
Colitis
Experimental colitis in mice is attenuated by changes in the levels of endocannabinoid metabolites induced by selective inhibition of fatty acid amide hydrolase (FAAH).
Colitis
Fatty acid amide hydrolase (FAAH) blockade ameliorates experimental colitis by altering microRNA expression and suppressing inflammation.
Colitis
Manipulation of the Endocannabinoid System in Colitis: A Comprehensive Review.
Colitis
The endogenous cannabinoid system protects against colonic inflammation.
Colonic Neoplasms
Fatty acid amide hydrolase (FAAH) inhibitor PF-3845 reduces viability, migration and invasiveness of human colon adenocarcinoma Colo-205 cell line: an in vitro study.
Colorectal Neoplasms
Possible endocannabinoid control of colorectal cancer growth.
Congenital Abnormalities
Anticholinesterase insecticide action at the murine male reproductive system.
Coronary Disease
Lipid hydrolase enzymes: pragmatic pro-longevity targets for improved human healthspan?
Cystitis
Attenuation of cystitis and pain sensation in mice lacking Fatty Acid amide hydrolase.
Cystitis
Fatty acid amide hydrolase inhibition normalises bladder function and reduces pain through normalising the anandamide/palmitoylethanolamine ratio in the inflamed bladder of rats.
Dementia, Vascular
Preservation of spatial memory and neuroprotection by the fatty acid amide hydrolase inhibitor URB597 in a rat model of vascular dementia.
Diabetes Mellitus
C358A missense polymorphism of the endocannabinoid degrading enzyme fatty acid amide hydrolase (FAAH) and insulin resistance in patients with diabetes mellitus type 2.
Diabetes Mellitus, Type 1
Involvement of endocannabinoid system, inflammation and apoptosis in diabetes induced liver injury: Role of 5-HT3 receptor antagonist.
Diabetes Mellitus, Type 2
Endocannabinoid hydrolase and cannabinoid receptor 1 are involved in the regulation of hypothalamus-pituitary-adrenal axis in type 2 diabetes.
Down Syndrome
Glial expression of cannabinoid CB(2) receptors and fatty acid amide hydrolase are beta amyloid-linked events in Down's syndrome.
Encephalitis
Genetic deletion of Fatty Acid Amide Hydrolase results in improved long-term outcome in chronic autoimmune encephalitis.
Encephalomyelitis
N-Acylethanolamine-Hydrolyzing Acid Amidase Inhibition, but Not Fatty Acid Amide Hydrolase Inhibition, Prevents the Development of Experimental Autoimmune Encephalomyelitis in Mice.
Encephalomyelitis, Autoimmune, Experimental
N-Acylethanolamine-Hydrolyzing Acid Amidase Inhibition, but Not Fatty Acid Amide Hydrolase Inhibition, Prevents the Development of Experimental Autoimmune Encephalomyelitis in Mice.
Endometrial Neoplasms
Expression and Function of the Endocannabinoid Modulating Enzymes Fatty Acid Amide Hydrolase and N-Acylphosphatidylethanolamine-Specific Phospholipase D in Endometrial Carcinoma.
Epilepsy
Subventricular zone neural progenitors protect striatal neurons from glutamatergic excitotoxicity.
fatty acid amide hydrolase deficiency
Fatty acid amide hydrolase deficiency enhances intraplaque neutrophil recruitment in atherosclerotic mice.
fatty acid amide hydrolase deficiency
Fatty acid amide hydrolase deficiency limits early pregnancy events.
Glaucoma
Identification of Bivalent Ligands with Melatonin Receptor Agonist and Fatty Acid Amide Hydrolase (FAAH) Inhibitory Activity That Exhibit Ocular Hypotensive Effect in the Rabbit.
Glioma
Anandamide metabolism by fatty acid amide hydrolase in intact C6 glioma cells. Increased sensitivity to inhibition by ibuprofen and flurbiprofen upon reduction of extra- but not intracellular pH.
Glioma
Interaction of ligands for the peroxisome proliferator-activated receptor gamma with the endocannabinoid system.
Granuloma
Levels of endocannabinoids and palmitoylethanolamide and their pharmacological manipulation in chronic granulomatous inflammation in rats.
Head Injuries, Closed
Therapeutic Effect of a Novel Fatty Acid Amide Hydrolase Inhibitor PF04457845 in the Repetitive Closed Head Injury Mouse Model.
Head Injuries, Penetrating
Fatty-acid amide hydrolase polymorphisms and post-traumatic stress disorder after penetrating brain injury.
Headache Disorders, Secondary
Inhibition of FAAH reduces nitroglycerin-induced migraine-like pain and trigeminal neuronal hyperactivity in mice.
Huntington Disease
Cannabinoid control of motor function at the basal ganglia.
Huntington Disease
Characterization of Endocannabinoid-Metabolizing Enzymes in Human Peripheral Blood Mononuclear Cells under Inflammatory Conditions.
Huntington Disease
Severe deficiency of the fatty acid amide hydrolase (FAAH) activity segregates with the Huntington's disease mutation in peripheral lymphocytes.
Hyperalgesia
Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase Inhibitors Produce Anti-Allodynic Effects in Mice Through Distinct Cannabinoid Receptor Mechanisms.
Hyperalgesia
Fatty acid amide hydrolase blockade attenuates the development of collagen-induced arthritis and related thermal hyperalgesia in mice.
Hyperalgesia
Impaired endocannabinoid signalling in the rostroventromedial medulla underpins genotype-dependent hyper-responsivity to noxious stimuli.
Hyperalgesia
Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms.
Hyperalgesia
Inhibition of fatty acid amide hydrolase suppresses referred hyperalgesia induced by bladder inflammation.
Hyperalgesia
Sensitization of C-fiber nociceptors in mice with sickle cell disease is decreased by local inhibition of anandamide hydrolysis.
Hyperalgesia
Therapeutic potential of inhibitors of endocannabinoid degradation for the treatment of stress-related hyperalgesia in an animal model of chronic pain.
Hyperalgesia
UPREGULATION OF FATTY ACID AMIDE HYDROLASE (FAAH) IN THE DORSAL PERIAQUEDUCTAL GRAY IS ASSOCIATED WITH NEUROPATHIC PAIN AND REDUCED HEART RATE IN RATS.
Hyperalgesia
URB597, an inhibitor of fatty acid amide hydrolase, reduces hyperalgesia in diabetic rats.
Hypertension
Beneficial Changes in Rat Vascular Endocannabinoid System in Primary Hypertension and under Treatment with Chronic Inhibition of Fatty Acid Amide Hydrolase by URB597.
Hypertension
Effects of hypertension and FAAH inhibitor treatment of rats with primary and secondary hypertension considering the physicochemical properties of erythrocytes.
Hypertension
Experimental Activation of Endocannabinoid System Reveals Antilipotoxic Effects on Cardiac Myocytes.
Hypertension
Inhibitor of fatty acid amide hydrolase normalizes cardiovascular function in hypertension without adverse metabolic effects.
Hypertension
Long-term administration of fatty acid amide hydrolase inhibitor (URB597) to rats with spontaneous hypertension disturbs liver redox balance and phospholipid metabolism.
Hypertension
QM/MM modelling of oleamide hydrolysis in fatty acid amide hydrolase (FAAH) reveals a new mechanism of nucleophile activation.
Hypertension
The Effect of Long-Term Administration of Fatty Acid Amide Hydrolase Inhibitor URB597 on Oxidative Metabolism in the Heart of Rats with Primary and Secondary Hypertension.
Hypertension
The Endocannabinoid System Affects Myocardial Glucose Metabolism in the DOCA-Salt Model of Hypertension.
Hypertension
The FAAH Inhibitor URB597 Modulates Lipid Mediators in the Brain of Rats with Spontaneous Hypertension.
Hypertension
The influence of DOCA-salt hypertension and chronic administration of the FAAH inhibitor URB597 on K
Hypothyroidism
Fatty acid amide hydrolase ablation promotes ectopic lipid storage and insulin resistance due to centrally mediated hypothyroidism.
Infarction, Middle Cerebral Artery
Modulation of the endocannabinoid system by focal brain ischemia in the rat is involved in neuroprotection afforded by 17beta-estradiol.
Insulin Resistance
C358A missense polymorphism of the endocannabinoid degrading enzyme fatty acid amide hydrolase (FAAH) and insulin resistance in patients with diabetes mellitus type 2.
Insulin Resistance
Effects of C358A missense polymorphism of the degrading enzyme fatty acid amide hydrolase on weight loss, adipocytokines, and insulin resistance after 2 hypocaloric diets.
Insulin Resistance
Effects of C358A polymorphism of the endocannabinoid degrading enzyme fatty acid amide hydrolase (FAAH) on weight loss, adipocytokines levels, and insulin resistance after a high polyunsaturated fat diet in obese patients.
Insulin Resistance
Fatty acid amide hydrolase ablation promotes ectopic lipid storage and insulin resistance due to centrally mediated hypothyroidism.
Insulin Resistance
Genetic variation in the endocannabinoid degrading enzyme fatty acid amide hydrolase (FAAH) and their influence on weight loss and insulin resistance under a high monounsaturated fat hypocaloric diet.
Insulin Resistance
Relation of C358A polymorphism of the endocannabinoid degrading enzyme fatty acid amide hydrolase (FAAH) with obesity and insulin resistance.
Insulin Resistance
Relationship among metabolic syndrome, C358A polymorphism of the endocannabinoid degrading enzyme fatty acid amide hydrolase (FAAH) and insulin resistance.
Intracranial Hemorrhages
Computational proteome-wide screening predicts neurotoxic drug-protein interactome for the investigational analgesic BIA 10-2474.
Irritable Bowel Syndrome
Association of cannabinoid type 1 receptor and fatty acid amide hydrolase genetic polymorphisms in Chinese patients with irritable bowel syndrome.
Ischemic Stroke
Subventricular zone neural progenitors protect striatal neurons from glutamatergic excitotoxicity.
Leukemia
The Roles of Anandamide, Fatty Acid Amide Hydrolase, and Leukemia Inhibitory Factor on the Endometrium during the Implantation Window.
Leukodystrophy, Metachromatic
Deletion of fatty acid amide hydrolase reduces lyso-sulfatide levels but exacerbates metachromatic leukodystrophy in mice.
Lung Injury
Posttreatment With the Fatty Acid Amide Hydrolase Inhibitor URB937 Ameliorates One-Lung Ventilation-Induced Lung Injury in a Rabbit Model.
Lung Injury
The Fatty Acid Amide Hydrolase Inhibitor URB937 Ameliorates Radiation-Induced Lung Injury in a Mouse Model.
Lung Neoplasms
Fatty acid amide hydrolase inhibitors confer anti-invasive and antimetastatic effects on lung cancer cells.
Lymphoma
Further insights into the regulation of human FAAH by progesterone and leptin implications for endogenous levels of anandamide and apoptosis of immune and neuronal cells.
Memory Disorders
Effects of URB597 as an inhibitor of fatty acid amide hydrolase on WIN55, 212-2-induced learning and memory deficits in rats.
Metabolic Diseases
Pain and beyond: fatty acid amides and fatty acid amide hydrolase inhibitors in cardiovascular and metabolic diseases.
Metabolic Syndrome
385 C/A polymorphism of the fatty acid amide hydrolase gene is associated with metabolic syndrome in the Chinese Han population.
Metabolic Syndrome
Relationship among metabolic syndrome, C358A polymorphism of the endocannabinoid degrading enzyme fatty acid amide hydrolase (FAAH) and insulin resistance.
Migraine Disorders
Distinct Activity of Endocannabinoid-Hydrolyzing Enzymes MAGL and FAAH in Key Regions of Peripheral and Central Nervous System Implicated in Migraine.
Migraine Disorders
Effects of peripheral FAAH blockade on NTG-induced hyperalgesia-evaluation of URB937 in an animal model of migraine.
Migraine Disorders
Emerging Role of (Endo)Cannabinoids in Migraine.
Migraine Disorders
Inhibition of FAAH reduces nitroglycerin-induced migraine-like pain and trigeminal neuronal hyperactivity in mice.
Migraine Disorders
Peripheral changes of endocannabinoid system components in episodic and chronic migraine patients: A pilot study.
Multiple Sclerosis
Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis.
Multiple Sclerosis
Cannabinoid control of motor function at the basal ganglia.
Myocardial Infarction
Endocannabinoids and the heart.
Neoplasm Metastasis
3-Hydroxypropane-1,2-Diyl Dipalmitoleate-A Natural Compound with Dual Roles (CB1 Agonist/FAAH1 Blocker) in Inhibiting Ovarian Cancer Cell Line.
Neoplasms
3-Hydroxypropane-1,2-Diyl Dipalmitoleate-A Natural Compound with Dual Roles (CB1 Agonist/FAAH1 Blocker) in Inhibiting Ovarian Cancer Cell Line.
Neoplasms
Antitumor Cannabinoid Chemotypes: Structural Insights.
Neoplasms
Brain permeant and impermeant inhibitors of fatty-acid amide hydrolase suppress the development and maintenance of paclitaxel-induced neuropathic pain without producing tolerance, physical dependence in vivo and synergize with paclitaxel to reduce tumor cell line viability in vitro.
Neoplasms
Characterization of fatty acid amide hydrolase activity by a fluorescence-based assay.
Neoplasms
Endocannabinoid system and the expression of endogenous ceramides in human hepatocellular carcinoma.
Neoplasms
Endocannabinoid system expression in ovarian epithelial tumors according to the dualistic model of ovarian carcinogenesis.
Neoplasms
Endocannabinoids as endometrial inflammatory markers in lactating Holstein cows.
Neoplasms
Immune-mediated activation of the endocannabinoid system in visceral adipose tissue in obesity.
Neoplasms
Involvement of endocannabinoid system, inflammation and apoptosis in diabetes induced liver injury: Role of 5-HT3 receptor antagonist.
Neoplasms
Ligands for cannabinoid receptors, promising anticancer agents.
Neoplasms
Modulation of the Endocannabinoid System as a Potential Anticancer Strategy.
Neoplasms
New Approaches to Cancer Therapy: Combining Fatty Acid Amide Hydrolase (FAAH) Inhibition with Peroxisome Proliferator-Activated Receptors (PPARs) Activation.
Neoplasms
Omega-3 N-acylethanolamines are endogenously synthesised from omega-3 fatty acids in different human prostate and breast cancer cell lines.
Neoplasms
Recent Trends in the Design, Synthesis and Biological Exploration of ?-Lactams.
Neoplasms
The Fatty Acid Amide Hydrolase Inhibitor URB937 Ameliorates Radiation-Induced Lung Injury in a Mouse Model.
Neoplasms
Update on the endocannabinoid system as an anticancer target.
Nervous System Diseases
Acute Neurologic Disorder from an Inhibitor of Fatty Acid Amide Hydrolase.
Nervous System Diseases
Development and characterization of a promising fluorine-18 labelled radiopharmaceutical for in vivo imaging of fatty acid amide hydrolase.
Nervous System Diseases
Elucidation of hydrolysis mechanisms for fatty acid amide hydrolase and its Lys142Ala variant via QM/MM simulations.
Nervous System Diseases
Synthesis and preclinical evaluation of [¹?F]FCHC for neuroimaging of fatty acid amide hydrolase.
Neuralgia
A Cocktail Interaction Study Evaluating the Drug-Drug Interaction Potential of the Perpetrator Drug ASP8477 at Multiple Ascending Dose Levels.
Neuralgia
Analgesic effects of fatty acid amide hydrolase inhibition in a rat model of neuropathic pain.
Neuralgia
Brain permeant and impermeant inhibitors of fatty-acid amide hydrolase suppress the development and maintenance of paclitaxel-induced neuropathic pain without producing tolerance, physical dependence in vivo and synergize with paclitaxel to reduce tumor cell line viability in vitro.
Neuralgia
Brain permeant and impermeant inhibitors of fatty-acid amide hydrolase synergize with the opioid analgesic morphine to suppress chemotherapy-induced neuropathic nociception without enhancing effects of morphine on gastrointestinal transit.
Neuralgia
Computational proteome-wide screening predicts neurotoxic drug-protein interactome for the investigational analgesic BIA 10-2474.
Neuralgia
Development of Potent Inhibitors of Fatty Acid Amide Hydrolase Useful for the Treatment of Neuropathic Pain.
Neuralgia
Drug Therapy of Neuropathic Pain: Current Developments and Future Perspectives.
Neuralgia
Full inhibition of spinal FAAH leads to TRPV1-mediated analgesic effects in neuropathic rats and possible lipoxygenase-mediated remodeling of anandamide metabolism.
Neuralgia
Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase.
Neuralgia
Inhibition of Fatty Acid Amide Hydrolase Improves Depressive-Like Behaviors Independent of Its Peripheral Antinociceptive Effects in a Rat Model of Neuropathic Pain.
Neuralgia
Inhibition of fatty acid amide hydrolase: a potential treatment for neuropathic pain.
Neuralgia
Pyrazole phenylcyclohexylcarbamates as inhibitors of human fatty acid amide hydrolases (FAAH).
Neuralgia
Scaffold hopping-guided design of some isatin based rigid analogs as fatty acid amide hydrolase inhibitors: Synthesis and evaluation.
Neuralgia
Systematic review and meta-analysis of cannabinoids, cannabis-based medicines, and endocannabinoid system modulators tested for antinociceptive effects in animal models of injury-related or pathological persistent pain.
Neuralgia
Targeting the cannabinoid system to produce analgesia.
Neuralgia
The case for the development of novel analgesic agents targeting both fatty acid amide hydrolase and either cyclooxygenase or TRPV1.
Neuralgia
The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain.
Neuralgia
The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice.
Neuralgia
The MOBILE Study-A Phase IIa Enriched Enrollment Randomized Withdrawal Trial to Assess the Analgesic Efficacy and Safety of ASP8477, a Fatty Acid Amide Hydrolase Inhibitor, in Patients with Peripheral Neuropathic Pain.
Neuralgia
The novel reversible fatty acid amide hydrolase inhibitor ST4070 increases endocannabinoid brain levels and counteracts neuropathic pain in different animal models.
Neuralgia
UPREGULATION OF FATTY ACID AMIDE HYDROLASE (FAAH) IN THE DORSAL PERIAQUEDUCTAL GRAY IS ASSOCIATED WITH NEUROPATHIC PAIN AND REDUCED HEART RATE IN RATS.
Neurobehavioral Manifestations
Effects of Fatty Acid Amide Hydrolase Inhibitors Acute Administration on the Positive and Cognitive Symptoms of Schizophrenia in Mice.
Neuroblastoma
Anandamide and 2-arachidonoylglycerol inhibit fatty acid amide hydrolase by activating the lipoxygenase pathway of the arachidonate cascade.
Neuroblastoma
Development of a potent inhibitor of 2-arachidonoylglycerol hydrolysis with antinociceptive activity in vivo.
Neuroblastoma
Does the hydrolysis of 2-arachidonoylglycerol regulate its cellular uptake?
Neuroblastoma
Evidence against the presence of an anandamide transporter.
Neuroblastoma
Further insights into the regulation of human FAAH by progesterone and leptin implications for endogenous levels of anandamide and apoptosis of immune and neuronal cells.
Neurodegenerative Diseases
Design and synthesis of new carbamates as inhibitors for fatty acid amide hydrolase and cholinesterases: Molecular dynamic, in vitro and in vivo studies.
Neuroinflammatory Diseases
Cannabinoid receptor agonist WIN55,212-2 and fatty acid amide hydrolase inhibitor URB597 ameliorate neuroinflammatory responses in chronic cerebral hypoperfusion model by blocking NF-?B pathways.
Neuroinflammatory Diseases
Endocannabinoids: A Promising Impact for Traumatic Brain Injury.
Neuroinflammatory Diseases
FAAH inhibition attenuates TLR3-mediated hyperthermia, nociceptive- and anxiety-like behaviour in female rats.
Neuroinflammatory Diseases
FAAH-mediated modulation of TLR3-induced neuroinflammation in the rat hippocampus.
Neuroinflammatory Diseases
Scaffold hopping-guided design of some isatin based rigid analogs as fatty acid amide hydrolase inhibitors: Synthesis and evaluation.
Niemann-Pick Disease, Type A
Inhibition of fatty acid amide hydrolase prevents pathology in neurovisceral acid sphingomyelinase deficiency by rescuing defective endocannabinoid signaling.
Obesity
Circulating Endocannabinoids and the Polymorphism 385C>A in Fatty Acid Amide Hydrolase (FAAH) Gene May Identify the Obesity Phenotype Related to Cardiometabolic Risk: A Study Conducted in a Brazilian Population of Complex Interethnic Admixture.
Obesity
Dysregulation of the endocannabinoid system in obesity.
Obesity
Effects of C358A missense polymorphism of the degrading enzyme fatty acid amide hydrolase on weight loss, adipocytokines, and insulin resistance after 2 hypocaloric diets.
Obesity
Fatty acid amide hydrolase ablation promotes ectopic lipid storage and insulin resistance due to centrally mediated hypothyroidism.
Obesity
Inhibition of cholinergic and non-cholinergic targets following subacute exposure to chlorpyrifos in normal and high fat fed male C57BL/6J mice.
Obesity
Lack of association between C385A functional polymorphism of the fatty acid amide hydrolase gene and polycystic ovary syndrome.
Obesity
Mutation screen and association studies for the fatty acid amide hydrolase (FAAH) gene and early onset and adult obesity.
Obesity
Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH).
Obesity
Racial and sex differences in the polymorphisms of the endocannabinoid receptor genes in obesity.
Obesity
Relation of C358A polymorphism of the endocannabinoid degrading enzyme fatty acid amide hydrolase (FAAH) with obesity and insulin resistance.
Obesity
The cDNA 385C to A missense polymorphism of the endocannabinoid degrading enzyme fatty acid amide hydrolase (FAAH) is associated with overweight/obesity but not with binge eating disorder in overweight/obese women.
Obesity
The influence of the fatty acid amide hydrolase 385C>A single nucleotide polymorphisms on obesity susceptibility.
Obesity
[C358A polymorphism of the endocannabinoid degrading enzyme fatty acid amide hydrolase (FAAH) and adipocytokine levels in the morbidly obese.]
Obesity, Morbid
Biomarkers of endocannabinoid system activation in severe obesity.
Obesity, Morbid
The fatty acid amide hydrolase (FAAH) Pro129Thr polymorphism is not associated with severe obesity in Greek subjects.
Osteoarthritis
A multi-target approach for pain treatment - dual inhibition of fatty acid amide hydrolase and TRPV1 in a rat model of osteoarthritis.
Osteoarthritis
Early blockade of joint inflammation with a fatty acid amide hydrolase inhibitor decreases end-stage osteoarthritis pain and peripheral neuropathy in mice.
Osteoarthritis
Local application of the endocannabinoid hydrolysis inhibitor URB597 reduces nociception in spontaneous and chemically induced models of osteoarthritis.
Overweight
Lack of association between C385A functional polymorphism of the fatty acid amide hydrolase gene and polycystic ovary syndrome.
Overweight
Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH).
Overweight
[C358A polymorphism of the endocannabinoid degrading enzyme fatty acid amide hydrolase (FAAH) and adipocytokine levels in the morbidly obese.]
Parkinson Disease
Cannabinoid control of motor function at the basal ganglia.
Parkinson Disease
Fatty acid amide hydrolase (FAAH) inhibition reduces L-DOPA-induced hyperactivity in the MPTP-lesioned non-human primate model of Parkinson's disease.
Parkinson Disease
Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson's disease.
Periodontitis
PF-3845, a Fatty Acid Amide Hydrolase Inhibitor, Directly Suppresses Osteoclastogenesis through ERK and NF-?B Pathways In Vitro and Alveolar Bone Loss In Vivo.
Peripheral Nerve Injuries
Localization of the endocannabinoid-degrading enzyme fatty acid amide hydrolase in rat dorsal root ganglion cells and its regulation after peripheral nerve injury.
Peripheral Nervous System Diseases
Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment.
Peripheral Nervous System Diseases
Early blockade of joint inflammation with a fatty acid amide hydrolase inhibitor decreases end-stage osteoarthritis pain and peripheral neuropathy in mice.
Peripheral Nervous System Diseases
QM/MM modelling of oleamide hydrolysis in fatty acid amide hydrolase (FAAH) reveals a new mechanism of nucleophile activation.
Peripheral Vascular Diseases
From cannabis to cannabinergics: new therapeutic opportunities.
Pheochromocytoma
Biosynthesis and degradation of bioactive fatty acid amides in human breast cancer and rat pheochromocytoma cells--implications for cell proliferation and differentiation.
Pneumonia
Lipopolysaccharide-induced pulmonary inflammation is not accompanied by a release of anandamide into the lavage fluid or a down-regulation of the activity of fatty acid amide hydrolase.
Polycystic Ovary Syndrome
Decreased expression of fatty acid amide hydrolase in women with polycystic ovary syndrome.
Polycystic Ovary Syndrome
Lack of association between C385A functional polymorphism of the fatty acid amide hydrolase gene and polycystic ovary syndrome.
Polycystic Ovary Syndrome
Restored Plasma Anandamide and Endometrial Expression of Fatty Acid Amide Hydrolase in Women With Polycystic Ovary Syndrome by the Combination Use of Diane-35 and Metformin.
Pregnancy, Ectopic
Elevated anandamide and related N-acylethanolamine levels occur in the peripheral blood of women with ectopic pregnancy and are mirrored by changes in peripheral Fatty Acid amide hydrolase activity.
Premature Birth
Metformin attenuates susceptibility to inflammation-induced preterm birth in mice with higher endocannabinoid levels.
Prostatic Neoplasms
Does the hydrolysis of 2-arachidonoylglycerol regulate its cellular uptake?
Prostatic Neoplasms
Expression and function of fatty acid amide hydrolase in prostate cancer.
Prostatic Neoplasms
Fatty acid amide hydrolase in prostate cancer: association with disease severity and outcome, CB1 receptor expression and regulation by IL-4.
Prostatic Neoplasms
Inhibition of the cellular uptake of anandamide by genistein and its analogue daidzein in cells with different levels of fatty acid amide hydrolase-driven uptake.
Seizures
Enhancement of endocannabinoid signaling protects against cocaine-induced neurotoxicity.
Seizures
Equipotent Inhibition of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase - Dual Targets of the Endocannabinoid System to Protect against Seizure Pathology.
Seizures
Increased seizure susceptibility and proconvulsant activity of anandamide in mice lacking fatty acid amide hydrolase.
Seizures
Modulation of Anticonvulsant Effects of Cannabinoid Compounds by GABA-A Receptor Agonist in Acute Pentylenetetrazole Model of Seizure in Rat.
Sepsis
Inhibition of endocannabinoid degradation in experimental endotoxemia reduces leukocyte adhesion and improves capillary perfusion in the gut.
Sepsis
The mRNA expression of fatty acid amide hydrolase in human whole blood correlates with sepsis.
Shock, Septic
The mRNA expression of fatty acid amide hydrolase in human whole blood correlates with sepsis.
sphingomyelin phosphodiesterase deficiency
Inhibition of fatty acid amide hydrolase prevents pathology in neurovisceral acid sphingomyelinase deficiency by rescuing defective endocannabinoid signaling.
Spinal Cord Injuries
Fatty acid amide hydrolase (FAAH) inhibitors exert pharmacological effects, but lack antinociceptive efficacy in rats with neuropathic spinal cord injury pain.
Starvation
Intestinal levels of anandamide and oleoylethanolamide in food-deprived rats are regulated through their precursors.
Stroke
Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: A neuroprotective therapeutic modality.
Stroke
Massive accumulation of N-acylethanolamines after stroke. Cell signalling in acute cerebral ischemia?
Tachycardia, Ventricular
Cardioprotective effects of fatty acid amide hydrolase inhibitor URB694, in a rodent model of trait anxiety.
Vascular Diseases
Cannabinoid system as a potential target for drug development in the treatment of cardiovascular disease.
Virus Diseases
FAAH inhibition attenuates TLR3-mediated hyperthermia, nociceptive- and anxiety-like behaviour in female rats.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.000089
(1H-benzo[d][1,2,3]triazol-1-yl)(4-(3-phenoxybenzyl)-piperazin-1-yl)-methanone
Homo sapiens
pH and temperature not specified in the publication
0.000708
(1H-benzo[d][1,2,3]triazol-1-yl)(4-(4-phenoxybenzyl)-piperazin-1-yl)-methanone hydrochloride
Homo sapiens
pH and temperature not specified in the publication
0.000015
(1H-imidazol-1-yl)(4-(3-phenoxybenzyl)piperazin-1-yl)methanone
Homo sapiens
pH and temperature not specified in the publication
0.0000034
(1H-imidazol-1-yl)(4-(4-phenoxy-benzyl)-piperazin-1-yl)-methanone hydrochloride
Homo sapiens
pH and temperature not specified in the publication
0.000023
(3H-[1,2,3]triazol[4,5-b]pyridin-3-yl)(4-(3-phenoxybenzyl)-piperazin-1-yl)-methanone
Homo sapiens
pH and temperature not specified in the publication
0.000005
(3R,4R)-4-acetoxy-3-((10R)-(t-butyldimethylsilyloxy)-ethyl)-azetidin-2-one
Homo sapiens
pH 7.4, 37°C
0.00162
(4-(bis(benzo[d][1,3]dioxol-5-yl)(hydroxy)methyl)-piperidin-1-yl)(1H-1,2,4-triazol-1-yl)methanone
Homo sapiens
pH and temperature not specified in the publication
0.00782
(S)-(4-oxo-1-pent-4-enoylazetidin-2-yl)methyl 2-(biphenyl-4-yl)acetate
Homo sapiens
pH 7.4, 37°C
0.00805
(S)-(4-oxo-1-pent-4-enoylazetidin-2-yl)methyl 3-(1H-indol-3-yl)propanoate
Homo sapiens
pH 7.4, 37°C
0.00091
(S)-(4-oxo-1-pent-4-enoylazetidin-2-yl)methyl biphenyl-4-carboxylate
Homo sapiens
pH 7.4, 37°C
0.00503
(S)-(4-oxo-1-pent-4-enoylazetidin-2-yl)methyl-4-phenylbutanoate
Homo sapiens
pH 7.4, 37°C
0.00000188
1,1,1,3,3,3-hexafluoropropan-2-yl 4-(3-phenoxybenzyl)piperazine-1-carboxylate
Homo sapiens
pH and temperature not specified in the publication
0.000028
1-[(3S)-1-[4-(1-benzofuran-2-yl)pyrimidin-2-yl]piperidin-3-yl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one
Homo sapiens
pH and temperature not specified in the publication
0.000031
1-[(3S)-2-oxo-1-(pent-4-enoyl)azetidin-3-yl]ethyl (benzyloxy)acetate
Homo sapiens
pH 7.4, 37°C
0.00031
1-[(3S)-2-oxo-1-(pent-4-enoyl)azetidin-3-yl]ethyl 4-(pyridin-4-yl)butanoate
Homo sapiens
pH 7.4, 37°C
0.000012
1-[(3S)-2-oxo-1-(pent-4-enoyl)azetidin-3-yl]ethyl biphenyl-4-ylacetate
Homo sapiens
pH 7.4, 37°C
0.00196
2,2,2-trichloroethyl 4-(bis(benzo[d][1,3]dioxol-5-yl)(hydroxy)methyl)piperidine-1-carboxylate
Homo sapiens
pH and temperature not specified in the publication
0.00000038
3'-carbamoylbiphenyl-3-yl undec-10-yn-1-ylcarbamate
Homo sapiens
pH 9.0, 37°C
0.00000165 - 0.00000399
3-pyridyl 4-(phenylcarbamoyl)piperidine-1-carboxylate
0.00000175
4-(3-phenoxybenzyl)-N-(4-methoxyphenyl)piperazine-1-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.00000199
4-(3-phenoxybenzyl)-N-(4-nitrophenyl)piperazine-1-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.00302
4-(3-phenoxybenzyl)-N-phenylpiperazine-1-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0000029
4-(3-phenyl-1,2,4-thiadiazol-5-yl)-N-(pyridazin-3-yl)piperazine-1-carboxamide
Homo sapiens
pH 9.0, 37°C
0.000283
4-(benzyloxy)phenyl butylcarbamate
Homo sapiens
pH 9.0, 37°C
0.00000163
4-nitrophenyl-4-(4-phenoxy-benzyl)-piperazine-1-carboxylate
Homo sapiens
pH and temperature not specified in the publication
0.00194
4-nitrophenyl-4-(bis(benzo[d][1,3]dioxol-5-yl)methyl)piperidine-1-carboxylate
Homo sapiens
pH and temperature not specified in the publication
0.000028
4-[2-(2,4-difluorophenyl)pyridin-4-yl]-N-(pyridazin-3-yl)piperazine-1-carboxamide
Homo sapiens
pH 9.0, 37°C
0.000023
4-[2-(2,4-difluorophenyl)pyrimidin-4-yl]-N-(pyridazin-3-yl)piperazine-1-carboxamide
Homo sapiens
pH 9.0, 37°C
0.000000072
4-[4-(2,3-difluorophenyl)pyrimidin-2-yl]-N-(pyridazin-3-yl)piperazine-1-carboxamide
Homo sapiens
pH 9.0, 37°C
0.00000043
4-[4-(2,4-difluorophenyl)-1,3-thiazol-2-yl]-N-(3,4-dimethyl-1,2-oxazol-5-yl)piperazine-1-carboxamide
Homo sapiens
pH 9.0, 37°C
0.0000022 - 0.00014
4-[4-(2,4-difluorophenyl)pyridin-2-yl]-N-(pyridazin-3-yl)piperazine-1-carboxamide
0.0000011
4-[4-(2,4-difluorophenyl)pyrimidin-2-yl]-N-(pyridazin-3-yl)piperazine-1-carboxamide
Homo sapiens
pH 9.0, 37°C
0.000000025
4-[4-(2,5-difluorophenyl)pyrimidin-2-yl]-N-(pyridazin-3-yl)piperazine-1-carboxamide
Homo sapiens
pH 9.0, 37°C
0.00000072
4-[4-(3,4-difluorophenyl)pyrimidin-2-yl]-N-(pyridazin-3-yl)piperazine-1-carboxamide
Homo sapiens
pH 9.0, 37°C
0.0000008
4-[4-(3,5-difluorophenyl)pyrimidin-2-yl]-N-(pyridazin-3-yl)piperazine-1-carboxamide
Homo sapiens
pH 9.0, 37°C
0.000036
4-[6-(2,4-difluorophenyl)pyridin-2-yl]-N-(pyridazin-3-yl)piperazine-1-carboxamide
Homo sapiens
pH 9.0, 37°C
0.0000015
4-[6-(2,4-difluorophenyl)pyrimidin-4-yl]-N-(pyridazin-3-yl)piperazine-1-carboxamide
Homo sapiens
pH 9.0, 37°C
0.0000051
5-(4-hydroxyphenyl)pentanesulfonyl fluoride
Homo sapiens
pH 7.4, 25°C
0.000005
6-bromo-N-(2-fluorophenyl)-1'H,4H-spiro[1,3-benzodioxine-2,4'-piperidine]-1'-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.000206
7-phenyl-1-(5-pyridin-2-yl-1,3-oxazol-2-yl)heptan-1-one
Homo sapiens
pH 9.0, 37°C
0.00195
benzyl 4-(dibenzo[d][1,3]dioxol-5-yl(hydroxy)methyl)-piperidine-1-carboxylate
Homo sapiens
pH and temperature not specified in the publication
0.0000017
N-(3,4-dimethyl-1,2-oxazol-5-yl)-4-(3-phenyl-1,2,4-thiadiazol-5-yl)piperazine-1-carboxamide
Homo sapiens
pH 9.0, 37°C
0.000011
N-phenyl-4-(3-phenyl-1,2,4-thiadiazol-5-yl)piperazine-1-carboxamide
Homo sapiens
pH 9.0, 37°C
0.000016
OL-135
Homo sapiens
pH and temperature not specified in the publication
0.000004
URB597
Homo sapiens
pH and temperature not specified in the publication
0.04252
[(2S)-4-oxo-1-(pent-4-enoyl)azetidin-2-yl]methyl (benzyloxy)acetate
Homo sapiens
pH 7.4, 37°C
0.08706
[(2S)-4-oxo-1-(pent-4-enoyl)azetidin-2-yl]methyl 4-(pyridin-2-yl)butanoate
Homo sapiens
pH 7.4, 37°C
0.173
[(2S)-4-oxo-1-(pent-4-enoyl)azetidin-2-yl]methyl 4-(pyridin-4-yl)butanoate
Homo sapiens
pH 7.4, 37°C
0.002
[1-(2-naphthylmethyl)triazol-4-yl]methyl N-cyclohexylcarbamate
Homo sapiens
pH 7.4, 37°C
0.0000245
[1-(m-tolylmethyl)triazol-4-yl]methyl N-cyclohexylcarbamate
Homo sapiens
pH 7.4, 37°C
0.0000215
[1-(o-tolylmethyl)triazol-4-yl]methyl N-cyclohexylcarbamate
Homo sapiens
pH 7.4, 37°C
0.0005
[1-(p-tolylmethyl)triazol-4-yl]methyl N-cyclohexylcarbamate
Homo sapiens
pH 7.4, 37°C
0.0000119
[1-[(2,6-difluorophenyl)methyl]triazol-4-yl]methyl N-cyclohexylcarbamate
Homo sapiens
pH 7.4, 37°C
0.0000062
[1-[(2-chlorophenyl)methyl]triazol-4-yl]methyl N-cyclohexylcarbamate
Homo sapiens
pH 7.4, 37°C
0.0000195
[1-[(2-cyanophenyl)methyl]triazol-4-yl]methyl N-cyclohexylcarbamate
Homo sapiens
pH 7.4, 37°C
0.0000446
[1-[(2-fluoro-3-methoxy-phenyl)methyl]triazol-4-yl]methyl N-cyclohexylcarbamate
Homo sapiens
pH 7.4, 37°C
0.0000099
[1-[(2-fluorophenyl)methyl]triazol-4-yl]methyl N-cyclohexylcarbamate
Homo sapiens
pH 7.4, 37°C
0.0000014
[1-[(2-methoxyphenyl)methyl]triazol-4-yl]methyl N-cyclohexylcarbamate
Homo sapiens
pH 7.4, 37°C
0.000154
[1-[(2-methoxyphenyl)methyl]triazol-4-yl]methyl N-[[1-[(2-methoxyphenyl)methyl]triazol-4-yl]methyl]carbamate
Homo sapiens
pH 7.4, 37°C
0.0000032
[1-[(2-methoxyphenyl)methyl]triazol-4-yl]methyl N-[[1-[(3-methoxyphenyl)methyl]triazol-4-yl]methyl]carbamate
Homo sapiens
pH 7.4, 37°C
0.0000076
[1-[(2-methoxyphenyl)methyl]triazol-4-yl]methyl N-[[1-[(4-methoxyphenyl)methyl]triazol-4-yl]methyl]carbamate
Homo sapiens
pH 7.4, 37°C
0.0000104
[1-[(3,5-difluorophenyl)methyl]triazol-4-yl]methyl N-cyclohexylcarbamate
Homo sapiens
pH 7.4, 37°C
0.0000036
[1-[(3,5-dimethoxyphenyl)methyl]triazol-4-yl]methyl N-cyclohexylcarbamate
Homo sapiens
pH 7.4, 37°C
0.0000132
[1-[(3-chlorophenyl)methyl]triazol-4-yl]methyl N-cyclohexylcarbamate
Homo sapiens
pH 7.4, 37°C
0.0000215
[1-[(3-cyanophenyl)methyl]triazol-4-yl]methyl N-cyclohexylcarbamate
Homo sapiens
pH 7.4, 37°C
0.0000121
[1-[(3-fluorophenyl)methyl]triazol-4-yl]methyl N-cyclohexylcarbamate
Homo sapiens
pH 7.4, 37°C
0.0000118
[1-[(3-methoxyphenyl)methyl]triazol-4-yl]methyl N-cyclohexylcarbamate
Homo sapiens
pH 7.4, 37°C
0.0000098
[1-[(3-methoxyphenyl)methyl]triazol-4-yl]methyl N-[[1-[(2-methoxyphenyl)methyl]triazol-4-yl]methyl]carbamate
Homo sapiens
pH 7.4, 37°C
0.0000039
[1-[(3-methoxyphenyl)methyl]triazol-4-yl]methyl N-[[1-[(3-methoxyphenyl)methyl]triazol-4-yl]methyl]carbamate
Homo sapiens
pH 7.4, 37°C
0.0000058
[1-[(3-methoxyphenyl)methyl]triazol-4-yl]methyl N-[[1-[(4-methoxyphenyl)methyl]triazol-4-yl]methyl]carbamate
Homo sapiens
pH 7.4, 37°C
0.000215
[1-[(4-chlorophenyl)methyl]triazol-4-yl]methyl N-cyclohexylcarbamate
Homo sapiens
pH 7.4, 37°C
0.002282
[1-[(4-cyanophenyl)methyl]triazol-4-yl]methyl N-cyclohexylcarbamate
Homo sapiens
pH 7.4, 37°C
0.0000955
[1-[(4-fluorophenyl)methyl]triazol-4-yl]methyl N-cyclohexylcarbamate
Homo sapiens
pH 7.4, 37°C
0.000627
[1-[(4-methoxyphenyl)methyl]triazol-4-yl]methyl N-cyclohexylcarbamate
Homo sapiens
pH 7.4, 37°C
0.000232
(1-benzothiophen-6-ylamino)([(E)-[1-(biphenyl-3-yl)ethylidene]amino]oxy)methanone
Homo sapiens
-
pH 8.4, 37°C
0.000537
(1-benzylpiperidin-4-yl)[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl]methanone
Homo sapiens
-
pH and temperature not specified in the publication
0.00109
(4-benzylpiperazin-1-yl)[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl]methanone
Homo sapiens
-
pH and temperature not specified in the publication
0.000116
(dodecylamino)[[(E)-[1-[3-(thiophen-2-yl)phenyl]ethylidene]amino]oxy]methanone
Homo sapiens
-
pH 8.4, 37°C
0.05
(phenylamino)[[(4-phenylcyclohexylidene)amino]oxy]methanone
Homo sapiens
-
pH 8.4, 37°C
0.000008
(phenylamino)[[(E)-[1-[3-(thiophen-2-yl)phenyl]ethylidene]amino]oxy]methanone
Homo sapiens
-
pH 8.4, 37°C
0.0002
(phenylamino)[[(E)-[1-[4-(thiophen-2-yl)phenyl]ethylidene]amino]oxy]methanone
Homo sapiens
-
pH 8.4, 37°C
0.001
([(E)-[1-(2,2'-bithiophen-5-yl)ethylidene]amino]oxy)(naphthalen-1-ylamino)methanone
Homo sapiens
-
pH 8.4, 37°C
0.001
([(E)-[1-(4-cyclohexylphenyl)ethylidene]amino]oxy)(naphthalen-1-ylamino)methanone
Homo sapiens
-
pH 8.4, 37°C
0.05
([(E)-[1-(biphenyl-3-yl)ethylidene]amino]oxy)(diphenylamino)methanone
Homo sapiens
-
pH 8.4, 37°C
0.00001
([(E)-[1-(biphenyl-3-yl)ethylidene]amino]oxy)(naphthalen-1-ylamino)methanone
Homo sapiens
-
pH 8.4, 37°C
0.000069
([(E)-[1-(biphenyl-3-yl)ethylidene]amino]oxy)(phenylamino)methanone
Homo sapiens
-
pH 8.4, 37°C
0.00022
([(E)-[1-(biphenyl-3-yl)ethylidene]amino]oxy)(piperidin-1-yl)methanone
Homo sapiens
-
pH 8.4, 37°C
0.000017
([(E)-[1-(biphenyl-3-yl)ethylidene]amino]oxy)[(4-fluorophenyl)amino]methanone
Homo sapiens
-
pH 8.4, 37°C
0.000028
([(E)-[1-(biphenyl-3-yl)ethylidene]amino]oxy)[(4-methoxyphenyl)amino]methanone
Homo sapiens
-
pH 8.4, 37°C
0.0001
([(E)-[1-(biphenyl-3-yl)ethylidene]amino]oxy)[(5-phenylpentyl)amino]methanone
Homo sapiens
-
pH 8.4, 37°C
0.05
([(E)-[1-(biphenyl-4-yl)ethylidene]amino]oxy)(dimethylamino)methanone
Homo sapiens
-
pH 8.4, 37°C
0.000401
([(E)-[1-(biphenyl-4-yl)ethylidene]amino]oxy)(naphthalen-1-ylamino)methanone
Homo sapiens
-
pH 8.4, 37°C
0.00076
([(E)-[1-(biphenyl-4-yl)ethylidene]amino]oxy)(phenylamino)methanone
Homo sapiens
-
pH 8.4, 37°C
0.00051
1,1,1-trifluoro-N-([1-[2-oxo-3-(4-phenoxyphenoxy)propyl]-1H-indazol-5-yl]carbamoyl)methanesulfonamide
Homo sapiens
-
37°C, pH 7.4, assay in brain microsomes, substrate N-(2-hydroxyethyl)-4-pyren-1-ylbutanamide
0.00048
1-(1H-benzimidazol-1-yl)-3-(4-octylphenoxy)propan-2-one
Homo sapiens
-
37°C, pH 7.4, assay in brain microsomes, substrate N-(2-hydroxyethyl)-4-pyren-1-ylbutanamide
0.000015
1-(1H-benzotriazol-1-yl)-3-(4-octylphenoxy)propan-2-one
Homo sapiens
-
37°C, pH 7.4, assay in brain microsomes, substrate N-(2-hydroxyethyl)-4-pyren-1-ylbutanamide
0.000024
1-(1H-benzotriazol-1-yl)-3-(4-phenoxyphenoxy)propan-2-one
Homo sapiens
-
pH and temperature not specified in the publication
0.000011
1-(1H-benzotriazol-1-yl)-3-[(3'-chloro[1,1'-biphenyl]-4-yl)oxy]propan-2-one
Homo sapiens
-
37°C, pH 7.4, assay in brain microsomes, substrate N-(2-hydroxyethyl)-4-pyren-1-ylbutanamide
0.000014
1-(1H-benzotriazol-1-yl)-3-[(3'-fluoro[1,1'-biphenyl]-4-yl)oxy]propan-2-one
Homo sapiens
-
37°C, pH 7.4, assay in brain microsomes, substrate N-(2-hydroxyethyl)-4-pyren-1-ylbutanamide
0.000021
1-(1H-benzotriazol-1-yl)-3-[(4'-chloro[1,1'-biphenyl]-4-yl)oxy]propan-2-one
Homo sapiens
-
37°C, pH 7.4, assay in brain microsomes, substrate N-(2-hydroxyethyl)-4-pyren-1-ylbutanamide
0.000012
1-(1H-benzotriazol-1-yl)-3-[(4'-fluoro[1,1'-biphenyl]-4-yl)oxy]butan-2-one
Homo sapiens
-
37°C, pH 7.4, assay in brain microsomes, substrate N-(2-hydroxyethyl)-4-pyren-1-ylbutanamide
0.000012
1-(1H-benzotriazol-1-yl)-3-[(4'-fluoro[1,1'-biphenyl]-4-yl)oxy]propan-2-one
Homo sapiens
-
37°C, pH 7.4, assay in brain microsomes, substrate N-(2-hydroxyethyl)-4-pyren-1-ylbutanamide
0.000013
1-(1H-benzotriazol-1-yl)-3-[([1,1'-biphenyl]-4-yl)oxy]butan-2-one
Homo sapiens
-
37°C, pH 7.4, assay in brain microsomes, substrate N-(2-hydroxyethyl)-4-pyren-1-ylbutanamide
0.0018
1-(1H-benzotriazol-1-yl)-3-[([1,1'-biphenyl]-4-yl)oxy]pentan-2-one
Homo sapiens
-
37°C, pH 7.4, assay in brain microsomes, substrate N-(2-hydroxyethyl)-4-pyren-1-ylbutanamide
0.000012
1-(1H-benzotriazol-1-yl)-3-[([1,1'-biphenyl]-4-yl)oxy]propan-2-one
Homo sapiens
-
37°C, pH 7.4, assay in brain microsomes, substrate N-(2-hydroxyethyl)-4-pyren-1-ylbutanamide
0.00041
1-(1H-imidazol-1-yl)-3-(4-octylphenoxy)propan-2-one
Homo sapiens
-
37°C, pH 7.4, assay in brain microsomes, substrate N-(2-hydroxyethyl)-4-pyren-1-ylbutanamide
0.00062
1-(1H-imidazo[4,5-b]pyridin-1-yl)-3-(4-octylphenoxy)propan-2-one
Homo sapiens
-
37°C, pH 7.4, assay in brain microsomes, substrate N-(2-hydroxyethyl)-4-pyren-1-ylbutanamide
0.0023
1-(1H-indazol-1-yl)-3-(4-octylphenoxy)propan-2-one
Homo sapiens
-
37°C, pH 7.4, assay in brain microsomes, substrate N-(2-hydroxyethyl)-4-pyren-1-ylbutanamide
0.0026
1-(1H-indazol-1-yl)-3-(4-phenoxyphenoxy)propan-2-one
Homo sapiens
-
37°C, pH 7.4, assay in brain microsomes, substrate N-(2-hydroxyethyl)-4-pyren-1-ylbutanamide
0.00041
1-(3H-imidazo[4,5-b]pyridin-3-yl)-3-(4-octylphenoxy)propan-2-one
Homo sapiens
-
37°C, pH 7.4, assay in brain microsomes, substrate N-(2-hydroxyethyl)-4-pyren-1-ylbutanamide
0.000053
1-(4-octylphenoxy)-3-(1H-1,2,4-triazol-1-yl)propan-2-one
Homo sapiens
-
37°C, pH 7.4, assay in brain microsomes, substrate N-(2-hydroxyethyl)-4-pyren-1-ylbutanamide
0.00084
1-(4-octylphenoxy)-3-(1H-pyrazol-1-yl)propan-2-one
Homo sapiens
-
37°C, pH 7.4, assay in brain microsomes, substrate N-(2-hydroxyethyl)-4-pyren-1-ylbutanamide
0.0016
1-(4-octylphenoxy)-3-(1H-pyrazolo[3,4-b]pyridin-1-yl)propan-2-one
Homo sapiens
-
37°C, pH 7.4, assay in brain microsomes, substrate N-(2-hydroxyethyl)-4-pyren-1-ylbutanamide
0.000093
1-(4-octylphenoxy)-3-(1H-pyrazolo[4,3-b]pyridin-1-yl)propan-2-one
Homo sapiens
-
37°C, pH 7.4, assay in brain microsomes, substrate N-(2-hydroxyethyl)-4-pyren-1-ylbutanamide
0.000039
1-(4-octylphenoxy)-3-(1H-tetrazol-1-yl)propan-2-one
Homo sapiens
-
37°C, pH 7.4, assay in brain microsomes, substrate N-(2-hydroxyethyl)-4-pyren-1-ylbutanamide
0.000049
1-(4-octylphenoxy)-3-(1H-[1,2,3]triazolo[4,5-b]pyridin-1-yl)propan-2-one
Homo sapiens
-
37°C, pH 7.4, assay in brain microsomes, substrate N-(2-hydroxyethyl)-4-pyren-1-ylbutanamide
0.000112
1-(4-octylphenoxy)-3-(2H-1,2,3-triazol-2-yl)propan-2-one
Homo sapiens
-
37°C, pH 7.4, assay in brain microsomes, substrate N-(2-hydroxyethyl)-4-pyren-1-ylbutanamide
0.000013
1-(4-octylphenoxy)-3-(2H-tetrazol-2-yl)propan-2-one
Homo sapiens
-
37°C, pH 7.4, assay in brain microsomes, substrate N-(2-hydroxyethyl)-4-pyren-1-ylbutanamide
0.000013
1-(4-octylphenoxy)-3-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)propan-2-one
Homo sapiens
-
37°C, pH 7.4, assay in brain microsomes, substrate N-(2-hydroxyethyl)-4-pyren-1-ylbutanamide
0.000008
1-(4-phenoxyphenoxy)-3-(2H-tetrazol-2-yl)propan-2-one
Homo sapiens
-
pH and temperature not specified in the publication
0.00055
1-(5-nitro-1H-indazol-1-yl)-3-(4-phenoxyphenoxy)propan-2-one
Homo sapiens
-
37°C, pH 7.4, assay in brain microsomes, substrate N-(2-hydroxyethyl)-4-pyren-1-ylbutanamide
0.0000029
1-([1,3]oxazolo[4,5-b]pyridin-2-yl)-6-phenylhexan-1-one
Homo sapiens
-
37°C, pH 7.4, assay in brain microsomes, substrate N-(2-hydroxyethyl)-4-pyren-1-ylbutanamide
0.0000114
1-benzothiophen-4-yl [4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl]carbamate
Homo sapiens
-
pH and temperature not specified in the publication
0.00211 - 0.99146
1-[(3R)-1-[4-(1-benzofuran-2-yl)pyrimidin-2-yl]piperidin-3-yl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one
0.000043
1-[([1,1'-biphenyl]-4-yl)oxy]-3-(1H-tetrazol-1-yl)propan-2-one
Homo sapiens
-
37°C, pH 7.4, assay in brain microsomes, substrate N-(2-hydroxyethyl)-4-pyren-1-ylbutanamide
0.0063
1-[([1,1'-biphenyl]-4-yl)oxy]-3-(2H-tetrazol-2-yl)butan-2-one
Homo sapiens
-
37°C, pH 7.4, assay in brain microsomes, substrate N-(2-hydroxyethyl)-4-pyren-1-ylbutanamide
0.000011
1-[([1,1'-biphenyl]-4-yl)oxy]-3-(2H-tetrazol-2-yl)propan-2-one
Homo sapiens
-
37°C, pH 7.4, assay in brain microsomes, substrate N-(2-hydroxyethyl)-4-pyren-1-ylbutanamide
0.000055
1-[2-oxo-3-(4-phenoxyphenoxy)propyl]-1H-indazole-5-carboxylic acid
Homo sapiens
-
37°C, pH 7.4, assay in brain microsomes, substrate N-(2-hydroxyethyl)-4-pyren-1-ylbutanamide
0.00503
1-[3-[(4'-chlorobiphenyl-4-yl)oxy]-2-oxopropyl]-1H-indole-5-carboxylic acid
Homo sapiens
-
pH and temperature not specified in the publication
0.0000075
1H-benzimidazol-4-yl [4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl]carbamate
Homo sapiens
-
pH and temperature not specified in the publication
0.0000069
1H-indol-4-yl [4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl]carbamate
Homo sapiens
-
pH and temperature not specified in the publication
0.0000306
2,3-dihydro-1,4-benzodioxin-5-yl [4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl]carbamate
Homo sapiens
-
pH and temperature not specified in the publication
0.01
2-(1H-benzotriazol-1-yl)-1-(5-phenoxy-1,3-benzoxazol-2-yl)ethan-1-one
Homo sapiens
-
pH and temperature not specified in the publication
0.0054
2-hydroxy-N-[1-[2-oxo-3-(4-phenoxyphenoxy)propyl]-1H-indazol-5-yl]acetamide
Homo sapiens
-
37°C, pH 7.4, assay in brain microsomes, substrate N-(2-hydroxyethyl)-4-pyren-1-ylbutanamide
0.0063
2-methoxy-N-[1-[2-oxo-3-(4-phenoxyphenoxy)propyl]-1H-indazol-5-yl]acetamide
Homo sapiens
-
37°C, pH 7.4, assay in brain microsomes, substrate N-(2-hydroxyethyl)-4-pyren-1-ylbutanamide
0.00006 - 0.000112
3'-carbamoyl[1,1'-biphenyl]-3-yl cyclohexylcarbamate
0.000084
3'-[(1E)-N-[(phenylcarbamoyl)oxy]ethanimidoyl]biphenyl-3-carboxamide
Homo sapiens
-
pH 8.4, 37°C
0.00063
3-(1H-benzotriazol-1-yl)-1-[([1,1'-biphenyl]-4-yl)oxy]butan-2-one
Homo sapiens
-
37°C, pH 7.4, assay in brain microsomes, substrate N-(2-hydroxyethyl)-4-pyren-1-ylbutanamide
0.0000573
3-pyridyl 4-(phenylcarbamoyl)piperidine-1-carboxylate
Homo sapiens
pH 8.0, 37°C, wild-type enzyme
0.0624
3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]-N,N-diethylazetidine-1-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.5
3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]-N-ethyl-N-(2-hydroxyethyl)azetidine-1-carboxamide
Homo sapiens
-
above, pH and temperature not specified in the publication
0.00654
3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]-N-methyl-N-(2-phenylethyl)azetidine-1-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.193
3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]-N-methyl-N-phenylazetidine-1-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000019
3-[([1,1'-biphenyl]-4-yl)oxy]-1-(1H-tetrazol-1-yl)butan-2-one
Homo sapiens
-
37°C, pH 7.4, assay in brain microsomes, substrate N-(2-hydroxyethyl)-4-pyren-1-ylbutanamide
0.000009
3-[([1,1'-biphenyl]-4-yl)oxy]-1-(2H-tetrazol-2-yl)butan-2-one
Homo sapiens
-
37°C, pH 7.4, assay in brain microsomes, substrate N-(2-hydroxyethyl)-4-pyren-1-ylbutanamide
0.000012
4-(3-phenyl-[1,2,4]thiadiazol-5-yl)piperazine-1-carboxylic acid phenylamide
Homo sapiens
JNJ-1661010, without preincubation
0.0000033
4-carbamoylnaphthalen-1-yl [4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl]carbamate
Homo sapiens
-
pH and temperature not specified in the publication
0.0000045
4-fluoronaphthalen-1-yl [4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl]carbamate
Homo sapiens
-
pH and temperature not specified in the publication
0.0000062
4-hydroxynaphthalen-1-yl [4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl]carbamate
Homo sapiens
-
pH and temperature not specified in the publication
0.000229
4-methoxynaphthalen-1-yl [4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl]carbamate
Homo sapiens
-
pH and temperature not specified in the publication
0.0000034
4-[([4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl]carbamoyl)oxy]naphthalene-1-carboxylic acid
Homo sapiens
-
pH and temperature not specified in the publication
0.000244
5,6,7,8-tetrahydronaphthalen-1-yl [4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl]carbamate
Homo sapiens
-
pH and temperature not specified in the publication
0.0111
azepan-1-yl[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl]methanone
Homo sapiens
-
pH and temperature not specified in the publication
0.0988
azetidin-1-yl[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl]methanone
Homo sapiens
-
pH and temperature not specified in the publication
0.000001
JP104
Homo sapiens
pH 9.0, 37°C
0.004
methyl [1-[2-oxo-3-(4-phenoxyphenoxy)propyl]-1H-indazol-5-yl]carbamate
Homo sapiens
-
37°C, pH 7.4, assay in brain microsomes, substrate N-(2-hydroxyethyl)-4-pyren-1-ylbutanamide
0.5
N,N-dibenzyl-3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidine-1-carboxamide
Homo sapiens
-
above, pH and temperature not specified in the publication
0.025
N-(phenylcarbamoyl)-3'-[(1E)-N-[(phenylcarbamoyl)oxy]ethanimidoyl]biphenyl-3-carboxamide
Homo sapiens
-
pH 8.4, 37°C
0.0047
N-([1-[2-oxo-3-(4-phenoxyphenoxy)propyl]-1H-indazol-5-yl]carbamoyl)benzenesulfonamide
Homo sapiens
-
37°C, pH 7.4, assay in brain microsomes, substrate N-(2-hydroxyethyl)-4-pyren-1-ylbutanamide
0.00077
N-([1-[2-oxo-3-(4-phenoxyphenoxy)propyl]-1H-indazol-5-yl]carbamoyl)methanesulfonamide
Homo sapiens
-
37°C, pH 7.4, assay in brain microsomes, substrate N-(2-hydroxyethyl)-4-pyren-1-ylbutanamide
0.5
N-benzyl-3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]-N-(2-hydroxyethyl)azetidine-1-carboxamide
Homo sapiens
-
above, pH and temperature not specified in the publication
0.00209
N-benzyl-3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]-N-methylazetidine-1-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.5
N-benzyl-3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]-N-[2-(dimethylamino)ethyl]azetidine-1-carboxamide
Homo sapiens
-
above, pH and temperature not specified in the publication
0.5
N-benzyl-3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidine-1-carboxamide
Homo sapiens
-
above, pH and temperature not specified in the publication
0.887
N-benzyl-3-[(R)-(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]-N-methylazetidine-1-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0408
N-benzyl-3-[(S)-(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]-N-methylazetidine-1-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00084
N-cyclohexyl-N'-[1-[2-oxo-3-(4-phenoxyphenoxy)propyl]-1H-indazol-5-yl]urea
Homo sapiens
-
37°C, pH 7.4, assay in brain microsomes, substrate N-(2-hydroxyethyl)-4-pyren-1-ylbutanamide
0.0016
N-ethyl-N'-[1-[2-oxo-3-(4-phenoxyphenoxy)propyl]-1H-indazol-5-yl]urea
Homo sapiens
-
37°C, pH 7.4, assay in brain microsomes, substrate N-(2-hydroxyethyl)-4-pyren-1-ylbutanamide
0.5
N-tert-butyl-3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidine-1-carboxamide
Homo sapiens
-
above, pH and temperature not specified in the publication
0.006
N-[1-[2-oxo-3-(4-phenoxyphenoxy)propyl]-1H-indazol-5-yl]-N'-phenylurea
Homo sapiens
-
37°C, pH 7.4, assay in brain microsomes, substrate N-(2-hydroxyethyl)-4-pyren-1-ylbutanamide
0.0039
N-[1-[2-oxo-3-(4-phenoxyphenoxy)propyl]-1H-indazol-5-yl]acetamide
Homo sapiens
-
37°C, pH 7.4, assay in brain microsomes, substrate N-(2-hydroxyethyl)-4-pyren-1-ylbutanamide
0.000002 - 0.0000051
N-[4-(4-methoxy-1,3-benzothiazol-2-yl)phenyl]-1-(thiophen-2-ylsulfonyl)piperidine-4-carboxamide
0.0000069
naphthalen-1-yl (3-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]propyl)carbamate
Homo sapiens
-
pH and temperature not specified in the publication
0.0000215
naphthalen-1-yl (4-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]butyl)carbamate
Homo sapiens
-
pH and temperature not specified in the publication
0.0000062
naphthalen-1-yl [3-[4-(2,3-dichlorophenyl)piperazin-1-yl]propyl]carbamate
Homo sapiens
-
pH and temperature not specified in the publication
0.0000064
naphthalen-1-yl [3-[4-(3-methoxyphenyl)piperazin-1-yl]propyl]carbamate
Homo sapiens
-
pH and temperature not specified in the publication
0.0000053
naphthalen-1-yl [3-[4-(3-methylphenyl)piperazin-1-yl]propyl]carbamate
Homo sapiens
-
pH and temperature not specified in the publication
0.0000486
naphthalen-1-yl [4-[4-(3-methoxyphenyl)piperazin-1-yl]butyl]carbamate
Homo sapiens
-
pH and temperature not specified in the publication
0.000013
naphthalen-1-yl [4-[4-(3-methylphenyl)piperazin-1-yl]butyl]carbamate
Homo sapiens
-
pH and temperature not specified in the publication
0.0000134
OL-135
Homo sapiens
pH 9.0, 37°C
0.0000243
oleoyl oxazolopyridine
Homo sapiens
-
recombinant enzyme, pH 7.3, 37°C
0.0021
phenyl [1-[2-oxo-3-(4-phenoxyphenoxy)propyl]-1H-indazol-5-yl]carbamate
Homo sapiens
-
37°C, pH 7.4, assay in brain microsomes, substrate N-(2-hydroxyethyl)-4-pyren-1-ylbutanamide
0.00000063
phenyl [4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl]carbamate
Homo sapiens
-
pH and temperature not specified in the publication
0.000112
piperidin-1-yl[[(E)-[1-[3-(thiophen-2-yl)phenyl]ethylidene]amino]oxy]methanone
Homo sapiens
-
pH 8.4, 37°C
0.0000573
pyridin-3-yl 4-(phenylcarbamoyl)piperidine-1-carboxylate
Homo sapiens
37°C, pH 8.0
0.00136
URB532
Homo sapiens
pH 9.0, 37°C
0.0053
[1-(4-phenoxyphenoxy)-3-(2H-tetrazol-2-yl)propan-2-yl]cyanamide
Homo sapiens
-
pH and temperature not specified in the publication
-
0.132
[3-[(2-chlorophenyl)(4-chlorophenyl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
Homo sapiens
-
above, pH and temperature not specified in the publication
0.206
[3-[(2-chloropyridin-3-yl)(2-methylphenyl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
Homo sapiens
-
pH and temperature not specified in the publication
0.00669
[3-[(2-chloropyridin-3-yl)(3,4-dichlorophenyl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
Homo sapiens
-
pH and temperature not specified in the publication
0.00717
[3-[(2-chloropyridin-3-yl)(3-methoxyphenyl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
Homo sapiens
-
pH and temperature not specified in the publication
0.00739
[3-[(2-chloropyridin-3-yl)(phenyl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
Homo sapiens
-
pH and temperature not specified in the publication
0.0366
[3-[(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
Homo sapiens
-
pH and temperature not specified in the publication
0.00501
[3-[(3-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
Homo sapiens
-
pH and temperature not specified in the publication
0.0247
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](1,3-dihydro-2H-isoindol-2-yl)methanone
Homo sapiens
-
pH and temperature not specified in the publication
0.5
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](2-hydroxypiperidin-1-yl)methanone
Homo sapiens
-
above, pH and temperature not specified in the publication
0.00504
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](2-methylpiperidin-1-yl)methanone
Homo sapiens
-
pH and temperature not specified in the publication
0.00682
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](3,4-dihydroisoquinolin-2(1H)-yl)methanone
Homo sapiens
-
pH and temperature not specified in the publication
0.135
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](3-hydroxypiperidin-1-yl)methanone
Homo sapiens
-
pH and temperature not specified in the publication
0.5
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](3-hydroxypyrrolidin-1-yl)methanone
Homo sapiens
-
above, pH and temperature not specified in the publication
0.0164
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](3-methylpiperidin-1-yl)methanone
Homo sapiens
-
pH and temperature not specified in the publication
0.0051
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](4,4-difluoropiperidin-1-yl)methanone
Homo sapiens
-
pH and temperature not specified in the publication
0.00225
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](4-fluoropiperidin-1-yl)methanone
Homo sapiens
-
pH and temperature not specified in the publication
0.037
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](4-hydroxypiperidin-1-yl)methanone
Homo sapiens
-
pH and temperature not specified in the publication
0.0286
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](4-methylpiperazin-1-yl)methanone
Homo sapiens
-
pH and temperature not specified in the publication
0.000423
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](4-methylpiperidin-1-yl)methanone
Homo sapiens
-
pH and temperature not specified in the publication
0.0279
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](morpholin-4-yl)methanone
Homo sapiens
-
pH and temperature not specified in the publication
0.0705
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](pyrrolidin-1-yl)methanone
Homo sapiens
-
pH and temperature not specified in the publication
0.0174
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl][4-(hydroxymethyl)piperidin-1-yl]methanone
Homo sapiens
-
pH and temperature not specified in the publication
0.0096
[3-[(4-chlorophenyl)(2-methylphenyl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
Homo sapiens
-
pH and temperature not specified in the publication
0.5
[3-[(6-chloropyridin-3-yl)(2-methylphenyl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
Homo sapiens
-
above, pH and temperature not specified in the publication
0.5
[3-[(S)-(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
Homo sapiens
-
above, pH and temperature not specified in the publication
0.00332
[3-[1,3-benzodioxol-5-yl(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
Homo sapiens
-
pH and temperature not specified in the publication
0.00809 - 0.0829
[3-[phenyl(pyridin-3-yl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
0.001
[[(E)-[1-[4-(2,5-dimethyl-1H-pyrrol-1-yl)phenyl]ethylidene]amino]oxy](naphthalen-1-ylamino)methanone
Homo sapiens
-
pH 8.4, 37°C
0.00000165
3-pyridyl 4-(phenylcarbamoyl)piperidine-1-carboxylate
Homo sapiens
pH 8.0, 37°C, mutant enzyme P129T
0.00000399
3-pyridyl 4-(phenylcarbamoyl)piperidine-1-carboxylate
Homo sapiens
pH 8.0, 37°C, wild-type enzyme
0.0000022
4-[4-(2,4-difluorophenyl)pyridin-2-yl]-N-(pyridazin-3-yl)piperazine-1-carboxamide
Homo sapiens
pH 9.0, 37°C
0.00014
4-[4-(2,4-difluorophenyl)pyridin-2-yl]-N-(pyridazin-3-yl)piperazine-1-carboxamide
Homo sapiens
pH 9.0, 37°C
0.00211
1-[(3R)-1-[4-(1-benzofuran-2-yl)pyrimidin-2-yl]piperidin-3-yl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one
Homo sapiens
-
pH 8.0, 30°C, substrate: N-(6-methoxypyridin-3-yl)octanamide
0.99146
1-[(3R)-1-[4-(1-benzofuran-2-yl)pyrimidin-2-yl]piperidin-3-yl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one
Homo sapiens
-
pH 8.0, 30°C, substrate: N-(6-methoxypyridin-3-yl)decanamide
0.00006
3'-carbamoyl[1,1'-biphenyl]-3-yl cyclohexylcarbamate
Homo sapiens
-
37°C, pH 7.4, assay in brain microsomes, substrate N-(2-hydroxyethyl)-4-pyren-1-ylbutanamide
0.0000884
3'-carbamoyl[1,1'-biphenyl]-3-yl cyclohexylcarbamate
Homo sapiens
-
pH 8.0, 30°C, substrate: N-(6-methoxypyridin-3-yl)octanamide
0.000112
3'-carbamoyl[1,1'-biphenyl]-3-yl cyclohexylcarbamate
Homo sapiens
-
pH 8.0, 30°C, substrate: N-(6-methoxypyridin-3-yl)decanamide
0.000002
N-[4-(4-methoxy-1,3-benzothiazol-2-yl)phenyl]-1-(thiophen-2-ylsulfonyl)piperidine-4-carboxamide
Homo sapiens
-
pH 8.0, 22°C, at 78 nM substrate anandamide
0.0000038
N-[4-(4-methoxy-1,3-benzothiazol-2-yl)phenyl]-1-(thiophen-2-ylsulfonyl)piperidine-4-carboxamide
Homo sapiens
-
pH 8.0, 22°C, at 0.01 mM substrate anandamide
0.0000051
N-[4-(4-methoxy-1,3-benzothiazol-2-yl)phenyl]-1-(thiophen-2-ylsulfonyl)piperidine-4-carboxamide
Homo sapiens
-
pH 8.0, 22°C, at 0.005 mM substrate anandamide
0.00809
[3-[phenyl(pyridin-3-yl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
Homo sapiens
-
pH and temperature not specified in the publication
0.0829
[3-[phenyl(pyridin-3-yl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
Homo sapiens
-
pH and temperature not specified in the publication
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Wei, B.Q.; Mikkelsen, T.S.; McKinney, M.K.; Lander, E.S.; Cravatt, B.F.
A second fatty acid amide hydrolase with variable distribution among placental mammals
J. Biol. Chem.
281
36569-36578
2006
Homo sapiens (O00519), Homo sapiens (Q6GMR7), Homo sapiens, Mus musculus (O08914), Mus musculus, Rattus norvegicus (P97612)
brenda
Fowler, C.J.; Jonsson, K.O.; Tiger, G.
Fatty acid amide hydrolase: biochemistry, pharmacology, and therapeutic possibilities for an enzyme hydrolyzing anandamide, 2-arachidonoylglycerol, palmitoylethanolamide, and oleamide
Biochem. Pharmacol.
62
517-26
2001
Homo sapiens, Mus musculus, Rattus norvegicus, Sus scrofa
brenda
Giang, D.K.; Cravatt, B.F.
Molecular characterization of human and mouse fatty acid amide hydrolases
Proc. Natl. Acad. Sci. USA
94
2238-2242
1997
Rattus norvegicus, Homo sapiens (O00519), Homo sapiens, Mus musculus (O08914), Mus musculus
brenda
Boger, D.L.; Sato, H.; Lerner, A.E.; Hedrick, M.P.; Fecik, R.A.; Miyauchi, H.; Wilkie, G.D.; Austin, B.J.; Patricelli, M.P.; Cravatt, B.F.
Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide
Proc. Natl. Acad. Sci. USA
97
5044-5049
2000
Homo sapiens, Rattus norvegicus
brenda
Karbarz, M.J.; Luo, L.; Chang, L.; Tham, C.S.; Palmer, J.A.; Wilson, S.J.; Wennerholm, M.L.; Brown, S.M.; Scott, B.P.; Apodaca, R.L.; Keith, J.M.; Wu, J.; Breitenbucher, J.G.; Chaplan, S.R.; Webb, M.
Biochemical and biological properties of 4-(3-phenyl-[1,2,4] thiadiazol-5-yl)-piperazine-1-carboxylic acid phenylamide, a mechanism-based inhibitor of fatty acid amide hydrolase
Anesth. Analg.
108
316-329
2009
Rattus norvegicus, Homo sapiens (Q6GMR7), Homo sapiens
brenda
Kaczocha, M.; Glaser, S.T.; Chae, J.; Brown, D.A.; Deutsch, D.G.
Lipid droplets are novel sites of N-acylethanolamine inactivation by fatty acid amide hydrolase-2
J. Biol. Chem.
285
2796-2806
2010
Homo sapiens
brenda
Rakers, C.; Zoerner, A.A.; Engeli, S.; Batkai, S.; Jordan, J.; Tsikas, D.
Stable isotope liquid chromatography-tandem mass spectrometry assay for fatty acid amide hydrolase activity
Anal. Biochem.
421
699-705
2012
Canis lupus familiaris, Homo sapiens
brenda
Tian, G.; Paschetto, K.A.; Gharahdaghi, F.; Gordon, E.; Wilkins, D.E.; Luo, X.; Scott, C.W.
Mechanism of inhibition of fatty acid amide hydrolase by sulfonamide-containing benzothiazoles: long residence time derived from increased kinetic barrier and not exclusively from thermodynamic potency
Biochemistry
50
6867-6878
2011
Homo sapiens, Rattus norvegicus
brenda
Gattinoni, S.; Simone, C.D.; Dallavalle, S.; Fezza, F.; Nannei, R.; Battista, N.; Minetti, P.; Quattrociocchi, G.; Caprioli, A.; Borsini, F.; Cabri, W.; Penco, S.; Merlini, L.; Maccarrone, M.
A new group of oxime carbamates as reversible inhibitors of fatty acid amide hydrolase
Bioorg. Med. Chem. Lett.
20
4406-4411
2010
Homo sapiens
brenda
Roughley, S.D.; Browne, H.; Macias, A.T.; Benwell, K.; Brooks, T.; D'Alessandro, J.; Daniels, Z.; Dugdale, S.; Francis, G.; Gibbons, B.; Hart, T.; Haymes, T.; Kennett, G.; Lightowler, S.; Matassova, N.; Mansell, H.; Merrett, A.; Misra, A.; Padfield, A.; Parsons, R.; Pratt, R.; Robertson, A.; Simmonite, H.; Tan, K.; Walls, S.B.; Wong, M.
Fatty acid amide hydrolase inhibitors. 3: tetra-substituted azetidine ureas with in vivo activity
Bioorg. Med. Chem. Lett.
22
901-906
2012
Homo sapiens, Rattus norvegicus
brenda
Zahov, S.; Drews, A.; Hess, M.; Schulze Elfringhoff, A.; Lehr, M.
1-(3-biaryloxy-2-oxopropyl)indole-5-carboxylic acids and related compounds as dual inhibitors of human cytosolic phospholipase A2alpha and fatty acid amide hydrolase
ChemMedChem
6
544-549
2011
Homo sapiens, Rattus norvegicus
brenda
Strittmatter, F.; Gandaglia, G.; Benigni, F.; Bettiga, A.; Rigatti, P.; Montorsi, F.; Gratzke, C.; Stief, C.; Colciago, G.; Hedlund, P.
Expression of fatty acid amide hydrolase (FAAH) in human, mouse, and rat urinary bladder and effects of FAAH inhibition on bladder function in awake rats
Eur. Urol.
61
98-106
2012
Homo sapiens, Mus musculus, Rattus norvegicus, Rattus norvegicus Sprague-Dawley
brenda
Mukhopadhyay, P.; Horvath, B.; Rajesh, M.; Matsumoto, S.; Saito, K.; Batkai, S.; Patel, V.; Tanchian, G.; Gao, R.Y.; Cravatt, B.F.; Hasko, G.; Pacher, P.
Fatty acid amide hydrolase is a key regulator of endocannabinoid-induced myocardial tissue injury
Free Radic. Biol. Med.
50
179-195
2011
Homo sapiens, Mus musculus, Mus musculus C57/BL6J
brenda
Min, X.; Thibault, S.T.; Porter, A.C.; Gustin, D.J.; Carlson, T.J.; Xu, H.; Lindstrom, M.; Xu, G.; Uyeda, C.; Ma, Z.; Li, Y.; Kayser, F.; Walker, N.P.; Wang, Z.
Discovery and molecular basis of potent noncovalent inhibitors of fatty acid amide hydrolase (FAAH)
Proc. Natl. Acad. Sci. USA
108
7379-7384
2011
Homo sapiens (O00519), Rattus norvegicus (P97612)
brenda
Kono, M.; Matsumoto, T.; Imaeda, T.; Kawamura, T.; Fujimoto, S.; Kosugi, Y.; Odani, T.; Shimizu, Y.; Matsui, H.; Shimojo, M.; Kori, M.
Design, synthesis, and biological evaluation of a series of piperazine ureas as fatty acid amide hydrolase inhibitors
Bioorg. Med. Chem.
22
1468-1478
2014
Homo sapiens (O00519), Rattus norvegicus (P97612), Rattus norvegicus Sprague-Dawley (P97612)
brenda
Korhonen, J.; Kuusisto, A.; van Bruchem, J.; Patel, J.Z.; Laitinen, T.; Navia-Paldanius, D.; Laitinen, J.T.; Savinainen, J.R.; Parkkari, T.; Nevalainen, T.J.
Piperazine and piperidine carboxamides and carbamates as inhibitors of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL)
Bioorg. Med. Chem.
22
6694-6705
2014
Homo sapiens (O00519)
brenda
Colombano, G.; Albani, C.; Ottonello, G.; Ribeiro, A.; Scarpelli, R.; Tarozzo, G.; Daglian, J.; Jung, K.M.; Piomelli, D.; Bandiera, T.
O-(triazolyl)methyl carbamates as a novel and potent class of fatty acid amide hydrolase (FAAH) inhibitors
ChemMedChem
10
380-395
2015
Homo sapiens (O00519), Homo sapiens, Rattus norvegicus (P97612), Rattus norvegicus SpragueDawley (P97612)
brenda
Caruano, J.; Feledziak, M.; Labar, G.; Michaux, C.; Perpete, E.A.; Muccioli, G.G.; Robiette, R.; Marchand-Brynaert, J.
(S)-1-(Pent-4-enoyl)-4-(hydroxymethyl)-azetidin-2-one derivatives as inhibitors of human fatty acid amide hydrolase (hFAAH): synthesis, biological evaluation and molecular modelling
J. Enzyme Inhib. Med. Chem.
29
654-662
2014
Homo sapiens (O00519), Homo sapiens
brenda
Alapafuja, S.O.; Nikas, S.P.; Bharathan, I.T.; Shukla, V.G.; Nasr, M.L.; Bowman, A.L.; Zvonok, N.; Li, J.; Shi, X.; Engen, J.R.; Makriyannis, A.
Sulfonyl fluoride inhibitors of fatty acid amide hydrolase
J. Med. Chem.
55
10074-10089
2012
Homo sapiens (O00519), Homo sapiens, Rattus norvegicus (P97612)
brenda
Dato, F.M.; Maassen, A.; Goldfuss, B.; Pietsch, M.
Characterization of fatty acid amide hydrolase activity by a fluorescence-based assay
Anal. Biochem.
546
50-57
2018
Homo sapiens
brenda
Zahov, S.; Garzinsky, D.; Hanekamp, W.; Lehr, M.
1-Heteroarylpropan-2-ones as inhibitors of fatty acid amide hydrolase Studies on structure-activity relationships and metabolic stability
Bioorg. Med. Chem.
25
825-837
2017
Homo sapiens
brenda
Watabiki, T.; Tsuji, N.; Kiso, T.; Ozawa, T.; Narazaki, F.; Kakimoto, S.
In vitro and in vivo pharmacological characterization of ASP8477 A novel highly selective fatty acid amide hydrolase inhibitor
Eur. J. Pharmacol.
815
42-48
2017
Homo sapiens (B2C6G4), Homo sapiens (O00519), Homo sapiens, Rattus norvegicus (P97612)
brenda
Althaus, J.; Hake, T.; Hanekamp, W.; Lehr, M.
1-(5-Carboxyindazol-1-yl)propan-2-ones as dual inhibitors of cytosolic phospholipase A2? and fatty acid amide hydrolase bioisosteric replacement of the carboxylic acid moiety
J. Enzyme Inhib. Med. Chem.
31
131-140
2016
Homo sapiens
brenda
Sundermann, T.; Hanekamp, W.; Lehr, M.
Structure-activity relationship studies on 1-heteroaryl-3-phenoxypropan-2-ones acting as inhibitors of cytosolic phospholipase A2alpha and fatty acid amide hydrolase replacement of the activated ketone group by other serine traps
J. Enzyme Inhib. Med. Chem.
31
653-663
2016
Homo sapiens
brenda
Micoli, A.; De Simone, A.; Russo, D.; Ottonello, G.; Colombano, G.; Ruda, G.; Bandiera, T.; Cavalli, A.; Bottegoni, G.
Aryl and heteroaryl N-[4-[4-(2,3-substituted-phenyl)piperazine-1-yl]alkyl]carbamates with improved physico-chemical properties as dual modulators of dopamine D3 receptor and fatty acid amide hydrolase
MedChemComm
7
537-541
2016
Homo sapiens
-
brenda